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HOW SUBTERRANEAN REGULATION HINDERS
INNOVATION IN ASSISTED REPRODUCTIVE
TECHNOLOGY
Myrisha S. Lewis †

Most scholars believe assisted reproductive technology is subject only to
minimal regulation, especially by the federal government. This belief, I contend, is
wrong. In this Article, I examine agency documents, statements by officials, and
letters that the U.S. Food and Drug Administration (FDA) has sent to physicians and
researchers over the past fifteen years to reveal an overlooked regulatory program.
The FDA has been targeting new forms of assisted reproductive technology that
involve small genetic modifications (advanced assisted reproductive technologies or
AARTs) through regulatory actions that receive little public, media, or scholarly
attention. I term this method of regulation “subterranean regulation.” Subterranean
regulatory actions chill research as many physicians and researchers halt their
research after receiving these letters or stop providing access to AARTs in the United
States.
The existence of this unconventional and largely unnoticed regulatory practice
raises a series of issues including whether the FDA should be regulating advanced
assisted reproductive technologies at all. Moreover, a hidden, ad hoc regulatory
practice is exactly the wrong kind of process to use when it comes to scientific
innovations in fraught ethical areas, which includes not only assisted reproductive
technology but also other DNA-modifying technologies such as gene editing
(including CRISPR-Cas9). Ultimately, I recommend a regulatory approach that is as
close to “minimal regulation” as possible.

† Assistant Professor, Howard University School of Law; J.D., Columbia Law School; A.B.,
Harvard College. For helpful suggestions and comments, I would like to thank Lori Andrews,
Bernadette Atauhene, Katharine Baker, Felice Batlan, Rabia Belt, Robert Bohrer, Alexander
Boni-Saenz, Marie Boyd, Elizabeth Emens, Philip Genty, Patrick Goold, Sarah Harding, Jenny
Ma, Nancy Marder, Kent McKeever, Jennifer Nou, Elizabeth Pendo, Maya Sabatello,
Christopher Schmidt, Carolyn Shapiro, Stephanie Stern, and workshop participants at Howard
University, Florida State University, St. Thomas University, the Chicago-Kent College of Law,
the California Western School of Law, the Chicago Junior Faculty Workshop, the Tenth Annual
Lutie A. Lytle Black Women Law Faculty Writing Workshop, and the American Society of
Comparative Law’s Younger Comparativists Global Conference, where I presented earlier
versions of this Article.
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INTRODUCTION
Commentators have described the regulatory environment
surrounding assisted reproductive technology as “limited,” “minimally
regulated,” and even “the Wild Wild West.” 1 This Article reveals,
however, that one important subset of assisted reproductive technology,
the subset that contains forms of assisted reproductive technology that
combine in vitro fertilization with the modification of small amounts of
DNA (referred to herein as advanced assisted reproductive technologies
or AARTs), is an exception to this general rule. 2 Instead, the FDA highly
regulates AARTs through an overlooked regulatory program that is
mostly administered through letters as opposed to clearly applicable
regulations. I term this method of regulation “subterranean regulation.”
The FDA uses subterranean regulation to regulate medical
techniques that are accompanied by ethical controversy including
cloning, advanced assisted reproductive technologies, and
unconventional methods of enhancing fertility. 3 Over the past fifteen
years, the FDA has sent “Untitled Letters” to practitioners who work on
advanced assisted reproductive technologies. 4 Untitled Letters are one
1 Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1693 (2008)
(“Here, the minimally regulated [assisted reproductive technology] industry thrives with
minimal state interference or attention to fetal health outcomes or risks to mothers or
fetuses.”); Alexander N. Hecht, The Wild Wild West: Inadequate Regulation of Assisted
Reproductive Technology, 1 HOUS. J. HEALTH L. & POL’Y 227, 228 (2001); see, e.g., NAOMI R.
CAHN, TEST TUBE FAMILIES: WHY THE FERTILITY MARKET NEEDS LEGAL REGULATION (2009);
Naomi R. Chan & Jennifer M. Collins, Eight Is Enough, 103 NW. U. L. COLLOQUY 501, 507
(2009) (“Currently, regulation over reproductive technology by the state and federal
government is limited. The fertility industry mostly self regulates through nonbinding
guidelines and suggested ethical practices, though there are various physician licensing
requirements.”); Judith F. Daar, Regulating Reproductive Technologies: Panacea or Paper Tiger?,
34 HOUS. L. REV. 609, 615 (1997) (“[Assisted reproductive technology] is subject to little formal
regulation . . . .”); see also DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND
POLITICS DRIVE THE COMMERCE OF CONCEPTION 5 (2006) (“In the United States, however,
regulatory and legislative authorities have largely ignored the market for reproductive services.
There are very few restrictions on fertility treatments and little regulation of providers.”);
Marsha Garrison, Regulating Reproduction, 76 GEO. WASH. L. REV. 1623 (2008); Hank Greely,
Cloning and Government Regulation, 53 HASTINGS L.J. 1085, 1089–90 (2002); Lars Noah,
Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55
FLA. L. REV. 603, 614–15 (2003).
2 This Article will refer to these types of assisted reproductive technologies which result in
small modifications of DNA which will be inherited by future generations as “advanced assisted
reproductive technologies.” Examples of these advanced assisted reproductive technologies
include cytoplasmic transfer and mitochondrial transfer, a technique which was recently
approved in the United Kingdom.
3 See infra note 132 (discussing Freedom of Information Act (FOIA) request 2016-4882
which provides information on the FDA’s regulation by letter of AUGMENT, a fertility
treatment created by an American company that revitalizes a woman’s eggs; the technique is
currently unavailable in the United States).
4 See infra note 132; see also Warning and Untitled Letters: FDA Transparency Initiative,
U.S. FOOD & DRUG ADMIN. (Dec. 20, 2011) [hereinafter Warning and Untitled Letters], https://

1242

CARDOZO LAW REVIEW

[Vol. 39:1239

type of communication that the FDA uses to inform companies and
individuals that they are violating federal law. 5
However, the FDA’s process of issuing these letters to AARTproviders differs from the usual methods that the FDA uses to inform
regulated entities of statutory violations, not only in the
comprehensiveness of the letters but also in the recordkeeping related to
these letters. For example, the FDA’s response to a Freedom of
Information Act (FOIA) request that I submitted related to the first
example of the FDA’s subterranean regulation of AARTs revealed that
the FDA is “unable” to locate the addressees of these letters to AARTproviders and that it does not maintain such letters in a centralized
document management system. 6 Thus, while the content of those letters
is available online, it is impossible to ascertain the scope of this type of
regulation without a list of addressees. In some instances of
subterranean regulation, the content of the letters is not even publicly
available on the FDA’s website, such as in the 2013 case of a letter and
subsequent communications between the FDA and a Massachusettsbased provider of innovative assisted reproductive technology services. 7
www.fda.gov/AboutFDA/Transparency/TransparencyInitiative/ucm284105.htm (“If a person
or firm violates the Federal Food, Drug and Cosmetic Act (FD&C Act), FDA may give them an
opportunity to take voluntary and prompt action to correct the violation before FDA initiates
an enforcement action. FDA will issue either a Warning Letter or an Untitled Letter, depending
upon the nature of the violation. . . . FDA uses Untitled Letters for violations that are not as
significant as those that trigger warning letters. Unlike a Warning Letter, an Untitled Letter
does not include a statement warning that failure to promptly correct a violation may result in
an enforcement action.”).
5 See Warning and Untitled Letters, supra note 4. Compare infra Appendix A, with
Appendices B–D (The letter in Appendix A does not contain any statutory citation, nor does it
explain how the Addressee’s actions allegedly violate the statutes that the FDA has
responsibility for enforcing. By comparison, Appendix B mentions at least two specific
statutes). Appendix C infra includes citations to specific statutory violations (e.g., 21 U.S.C.
§§ 321(n), 352(a) (2012)), as does Appendix D (e.g., “This product is a device within the
meaning of section 201(h) of the FD&C Act, 21 U.S.C. § 321(h), because it is . . . .”).
6 FOIA Request 2016-4883 revealed that the FDA was unable to “locate an admin file for
the subject . . . letter.” E-mail from Ashlee Eswara, Microbiologist, U.S. Food & Drug Admin.,
to author (Aug. 25, 2016, 8:27 AM) (on file with author). Similarly, before the request was
officially closed, a conversation with an FDA employee in the FOIA division indicated that it
was unlikely that the Agency would be able to find the file related to the letter because the
Agency does not have a system for recordkeeping when an application is not active. Id.
7 See Letter from Ellen Lazarus, Dir., Div. of Human Tissues, Office of Cellular, Tissue &
Gene Therapies, U.S. Food & Drug Admin., to Alison Lawton, Chief Operating Officer,
OvaScience, Inc. (Apr. 9, 2013) (on file with author); Letter from Celia M. Witten, Dir., Office
of Cellular, Tissue and Gene Therapies, U.S. Food & Drug Admin., to Alison Lawton, Chief
Operating Officer, OvaScience, Inc. (Sept. 6, 2013) (on file with author); infra text
accompanying notes 179–83 (regarding FOIA Request 2016-4882 and Massachusetts-based
OvaScience’s AUGMENT technology which is now available in other countries but not the
United States, and the FDA’s most recent 2017 letter to Dr. John Zhang); see also Ariana
Eunjung Cha, FDA Cracks Down on Company Marketing “Three-Parent” Babies, WASH. POST
(Aug. 8, 2017), https://www.washingtonpost.com/news/to-your-health/wp/2017/08/07/fdacracks-down-on-company-marketing-three-parent-babies/?utm_term=.0562ad833f54.
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Nevertheless, my review of Agency FOIA responses, media coverage,
and, in the case of the aforementioned Massachusetts-based company, a
shareholder suit, have enabled me to identify some of the recipients of
the FDA’s subterranean letters, even in the absence of the Agency’s
“admin file.”
The first of the FDA’s subterranean letters to AART-providers was
sent on July 6, 2001 to physicians who were providing an advanced
assisted reproductive technology called “cytoplasmic transfer” to
patients. 8 The letter began by stating “[w]e want to advise you that the
Food and Drug Administration (FDA) has jurisdiction over human cells
used in therapy involving the transfer of genetic material by means
other than the union of gamete nuclei.” 9 While two federal statutes were
mentioned in the letter, there was no citation to any statutory provision
that would provide the FDA’s “jurisdiction.”10 Even though the Agency
provided no legal citation, the FDA still stated that physicians working
on advanced assisted reproductive technologies would have to submit to
the extensive drug approval process that applies to pharmaceutical
companies seeking to market new drugs in the United States. 11
In subsequent communications, including guidance documents
and other documents posted on the Agency’s website, the FDA has
ordered that all advanced assisted reproductive technologies, including
mitochondrial transfer, a potentially life-saving technique that has been
the subject of recent media coverage, obtain premarket approval prior to
clinical use. 12 However, just as with cytoplasmic transfer in 2001, the
8 See infra Appendix A; see also, e.g., Transcript of Center for Biologics Evaluation and
Research, Food and Drug Administration, Biological Response Modifiers Advisory Committee
Open Session Meeting #32, 47 (May 9, 2002, 8:00 AM) [hereinafter Meeting #32 Transcript],
https://www.fda.gov/OHRMS/DOCKETS/ac/02/transcripts/3855t1-01.pdf (“FDA had concerns
about whether we understood all the ramifications of this procedure and whether we
understood its safety in particular, and reacted by sending letters to practitioners who were
identified by publications on ooplasm [cytoplasm] transfer or by advertisements offering the
procedure. We advised practitioners that we would now require the submission of an
investigational new drug application, or IND, to the agency and its subsequent review to
continue to treat new patients.”).
9 See infra Appendix A. While the content of the letter is available on the FDA’s website,
the list of recipients is not. See supra note 6.
10 See infra Appendix A; see also discussion infra Part II (discussing how, by not providing
a specific statutory provision in its Untitled Letters, this action differs from the FDA’s usual
practice of clearly identifying an addressee’s illegal actions and the exact statutory provision
that those actions violate).
11 The letter stated that “[t]he use of such genetically manipulated cells (and/or their
derivatives) in humans constitutes a clinical investigation and requires submission of an
Investigational New Drug application (IND) to FDA,” which was followed by a confusing
sentence later in the letter that stated “[w]e can advise you whether or not your activities
require submission of an IND.” Infra Appendix A.
12 See, e.g., PARLIAMENTARY OFFICE OF SCI. & TECH., PREVENTING MITOCHONDRIAL
DISEASE (Mar. 2013) [hereinafter PREVENTING MITOCHONDRIAL DISEASE], http://
researchbriefings.files.parliament.uk/documents/POST-PN-431/POST-PN-431.pdf (providing
a brief, but detailed overview of mitochondrial disease and its advantages and disadvantages.
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FDA has provided no clear explanation of the source of its jurisdiction
over these techniques or why this divergence from the Agency’s “handsoff” treatment of conventional assisted reproductive technology is
justified. 13 After receiving the FDA’s letters, physicians stopped
providing access to advanced assisted reproductive technologies in the
United States. 14 Recent media coverage, for example, has focused on
New York–based physicians who traveled to Mexico to provide
mitochondrial transfer to a couple, explaining that “[t]o save lives is the
ethical thing to do.”15
This Article is the first article to combine the analysis of
cytoplasmic transfer, mitochondrial transfer, and cloning to reveal that
the FDA’s subterranean regulation of advanced assisted reproductive
technologies is based on the FDA’s successful banning of human
reproductive cloning in the United States through agency-issued letters
in 1998. It is also the first article to review primary sources including
FOIA requests (and responses) in order to posit that the FDA’s
regulation of genetic modifications in reproduction is driven, at least
partially, by ethical objections in addition to a lack of jurisdiction over
This document was created before the United Kingdom (U.K.) Parliament approved
regulations permitting mitochondrial transfer in the United Kingdom); Steve Connor, ThreeParent Baby Pioneer: “The Brits Will Be Ahead of the World”; Despite the Death of Prematurely
Born Twins, the Doctor Behind a Revolutionary Fertility Technique Tells Steve Connor It Is Safe,
INDEPENDENT (Jan. 17, 2015), https://advance.lexis.com/api/permalink/a59bd3b8-c233-45269937-48e9a66c1e07/?context=1000516; see also FDA Regulation of Human Cells, Tissues, and
Cellular and Tissue-Based Products (HCT/P’s) Product List, U.S. FOOD & DRUG ADMIN.
[hereinafter FDA Regulation of Human Cells], https://www.fda.gov/biologicsbloodvaccines/
tissuetissueproducts/regulationoftissues/ucm150485.htm (last updated Feb. 2, 2018).
13 See Sabrina Tavernise, His Fertility Advance Draws Ire: Shoukhrat Mitalipov’s
Mitochondrial Manipulations, N.Y. TIMES (Mar. 17, 2014), http://www.nytimes.com/2014/03/
18/science/shoukhrat-mitalipovs-mitochrondrial-manipulations.html (“Dr. Dorsa said the
university still has not decided whether to formally ask the F.D.A. for permission to move
forward with clinical trials.”). As of July 12, 2016, the university still had not submitted an
investigational new drug application to the FDA. See FDA Regulation of Human Cells, supra
note 12 (where the FDA lists “HUMAN CELLS USED IN THERAPY INVOLVING THE
TRANSFER OF GENETIC MATERIAL” listing “cell nuclei, oocyte nuclei, mitochondrial
genetic material in ooplasm, genetic material contained in a genetic vector” as products that are
regulated under “Section 351 of the [Public Health Service] Act and/or the [Food, Drug &
Cosmetic] Act” without explaining how the communicable disease provision of the Public
Health Service Act “and/or” the Food, Drug, and Cosmetic Act applies to these products); see
also discussion infra Part II (explaining that the application of the FDA’s Human Tissue
Regulations to human reproductive tissue is counterintuitive and contradictory).
14 See Meeting #32 Transcript, supra note 8; infra text accompanying note 87.
15 Michelle Roberts, First “Three Person Baby” Born Using New Method, BBC NEWS (Sept.
27, 2016), http://www.bbc.com/news/health-37485263; see also Denise Grady, Pregnancy
Created Using Egg Nucleus of Infertile Woman, N.Y. TIMES (Oct. 14, 2003), http://
www.nytimes.com/2003/10/14/us/pregnancy-created-using-egg-nucleus-of-infertilewoman.html (citing Dr. James Grifo, one of the physicians targeted by FDA letters on
cytoplasmic transfer: “Dr. Grifo said he and his colleagues gave their findings to doctors in
China because regulations imposed by the United States Food and Drug Administration in
2001 made it too difficult to continue the research in the United States.”).
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these forms of technology that happen to inhabit areas fraught with
ethical concerns and political opposition. 16 In addition to submitting
FOIA requests related to the content and scope of subterranean letters, I
analyzed other primary sources, including Federal Register issuances,
responses to FOIA requests, communications with researchers,
congressional testimony, and FDA Advisory Committee meeting
transcripts. 17 A review of these primary sources indicates that
sometimes FDA employees misunderstand the science underlying
AARTs and at other times, these employees attempt to muddle ethical
opposition with safety concerns in order to prevent the clinical use of
technology that the FDA deems objectionable. 18
16 See Susan L. Crockin & Gary A. Debele, Ethical Issues in Assisted Reproduction: A Primer
for Family Law Attorneys, 27 J. AM. ACAD. MATRIM. LAW. 289, 301 (2015); Judith Daar, MultiParty Parenting in Genetics and Law: A View from Succession, 49 FAM. L.Q. 71, 74 (2015); John
A. Robertson, Oocyte Cytoplasmic Transfers and the Ethics of Germ-Line Intervention, 26 J.L.
MED. & ETHICS 211 (1998). Some scholars have speculated on the possible reasons for the
FDA’s decision to assert jurisdiction over specific technologies such as cloning or cytoplasmic
transfer from a regulatory or statutory perspective. See, e.g., Lori B. Andrews, Is There a Right to
Clone? Constitutional Challenges to Bans on Human Cloning, 11 HARV. J.L. & TECH. 643, 669
(1998); Valarie K. Blake, Ovaries, Testicles, and Uteruses, Oh My! Regulating Reproductive
Tissue Transplants, 19 WM. & MARY J. WOMEN & L. 353 (2013); Clarke D. Forsythe, Human
Cloning and the Constitution, 32 VAL. U. L. REV. 469, 470 (1998); Kerry Lynn Macintosh, Brave
New Eugenics: Regulating Assisted Reproductive Technologies in the Name of Better Babies, 2010
U. ILL. J.L. TECH. & POL’Y 257, 271–74; Elizabeth C. Price, Does the FDA Have Authority to
Regulate Human Cloning?, 11 HARV. J.L. & TECH. 619, 628 (1998); see also Gregory J. Rokosz,
Human Cloning: Is the Reach of FDA Authority Too Far a Stretch?, 30 SETON HALL L. REV. 464,
468 (2000).
17 See Telephone Conference with Rachael Anatol & Celia Witten, U.S. Food & Drug
Admin., and Michelle Dipp & Allison Lawton, OvaScience, Inc. (Sept. 9, 2013) (summary of
teleconference on file with author); E-mail from Michelle Dipp, CEO, OvaScience, Inc., to Celia
M. Witten, Dir., Office of Cellular, Tissue & Gene Therapies, U.S. Food & Drug Admin. (Sept.
10, 2013, 5:25 PM) (on file with author); Letter from Ellen Lazarus, Dir., Office of Cellular,
Tissue & Gene Therapies, U.S. Food & Drug Admin., to Alison Lawton, Chief Operating
Officer, OvaScience, Inc. (Apr. 9, 2013) (on file with author); E-mail from Alison Lawton, Chief
Operating Officer, OvaScience, Inc., to Patrick Riggins, Branch Chief, U.S. Food and Drug
Admin. (Jan. 28, 2013, 12:37 PM) (on file with author); Telephone Conference with Richard
McFarland & Lori Tull, U.S. Food & Drug Admin., and Karen Nichols, OvaScience, Inc. (Dec.
20, 2013) (record of telephone conversation on file with author); E-mail from Patrick Riggins,
Branch Chief, U.S. Food & Drug Admin., to unknown recipient (Aug. 22, 2013, 12:38 PM) (on
file with author); E-mail from Celeste Smith, FOIA Officer, U.S. Food & Drug Admin., to
author (Sept. 9, 2016, 10:08 AM) (on file with author); Letter from Catherine Wilusz,
Consumer Safety Officer, U.S. Food & Drug Admin., to author (July 8, 2016) (on file with
author); E-mail from John Wright, Admin. Proceedings Specialist, U.S. Food & Drug Admin.,
on behalf of Dynna Bigby, Supervisory Admin. Proceedings Officer, U.S. Food & Drug Admin.,
to author (Aug. 14, 2016, 11:23 AM) (on file with author); E-mail from Ashlee Eswara to
author, supra note 6; Letter from Celia M. Witten to Alison Lawton, supra note 7; see also
discussion infra Parts III–IV.
18 See Meeting #32 Transcript, supra note 8 (“FDA had concerns about whether we
understood all the ramifications of this procedure and whether we understood its safety in
particular, and reacted by sending letters to practitioners who were identified by publications
on ooplasm [cytoplasm] transfer or by advertisements offering the procedure. We advised
practitioners that we would now require the submission of an investigational new drug
application, or IND, to the agency and its subsequent review to continue to treat new
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This Article makes several contributions to the literature. My
descriptive claim is that the FDA is regulating by letter in the area of
advanced assisted reproductive technologies. This expands the
administrative law literature by identifying and describing another
“informal tool” that federal agencies may use to regulate industries. 19 In
this Article, I both identify the concept of subterranean regulation and
offer an explanation as to why the FDA might be using it. After
explaining how the FDA regulates AARTs in a subterranean fashion, I
argue that the FDA should not be regulating advanced assisted
reproductive technologies in a subterranean manner or in any other
manner that subjects them to unique federal regulation. First, it is likely
that the FDA lacks jurisdiction over AARTs under applicable statutes,
namely the Food, Drug and Cosmetic Act and the Public Health Service
Act. 20 Second, AARTs do not fall within the categories of products that
the FDA regulates, and the FDA’s regulatory scheme is not structured to
objectively regulate them. Third, the result of the use of the FDA’s
overlooked regulatory program has been to allow the FDA to insert
ethical concerns into its regulation of assisted reproductive technology,
which is an inappropriate action for an administrative agency that has
been tasked with addressing the safety and effectiveness of regulated
products such as drugs and medical devices. 21 Ultimately, the Article is
driven by an effort to render the regulation of AARTs as transparent as
possible.
The Article proceeds as follows. Part I provides an overview of
advanced assisted reproductive technologies. Part II analyzes the
jurisdictional issues related to mitochondrial transfer and other
advanced assisted reproductive technologies including the confusion
over whether the agency’s enabling statutes apply to these technologies.
Part II also analyzes the differences between AARTs and the standard
categories of products regulated by the FDA (i.e., food, drugs, medical
devices, and biologics). 22 I also explain the concept of “subterranean
patients.”). For a general overview of the ethical issues that arise as a result of mitochondrial
transfer, see César Palacios-González, Ethics of Mitochondrial Replacement Techniques: A
Habermasian Perspective, 31 BIOETHICS 27 (2017).
19 Tim Wu, Agency Threats, 60 DUKE L.J. 1841, 1841–42 (2011); see also Lars Noah,
Administrative Arm-Twisting in the Shadow of Congressional Delegations of Authority, 1997
WIS. L. REV. 873 (1997).
20 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301–99h (2012); Public Health
Service Act, 42 U.S.C. §§ 201–300mm-61 (2012).
21 See FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 129 (2000) (“Under 21
U.S.C. § 360j(e), the agency may ‘require that a device be restricted to sale, distribution, or
use . . . upon such other conditions as [the FDA] may prescribe in such regulation, if, because
of its potentiality for harmful effect or the collateral measures necessary to its use, [the FDA]
determines that there cannot otherwise be reasonable assurance of its safety and
effectiveness.’”).
22 See What Does FDA Regulate?, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
AboutFDA/Transparency/Basics/ucm194879.htm (last updated Jan. 23, 2018).
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regulation,” using the regulation of AARTs as a starting point. Part III
explains how longstanding concerns about ethical issues, which are
mentioned in FDA officials’ public statements but not included in their
written communications with physicians and researchers, help explain
why the FDA regulates advanced assisted reproductive technologies in a
subterranean fashion. Part IV explains why the FDA should not be
regulating AARTs at all. Part IV also observes that the same ethical
issues that accompany advanced assisted reproductive technologies also
accompany other developing technologies that may modify the human
genetic code in order to treat disease, such as genome editing through
CRISPR-Cas9, a technique that has received substantial media coverage
not only due to its exciting treatment possibilities but also due to
surrounding patent litigation, and other technologies that allow for the
editing of genes. 23 In other words, the conditions that allow for and
motivate subterranean regulation in the field of assisted reproductive
technology such as political pressure, ethical opposition, scientific
misunderstanding, and lack of federal agency jurisdiction, will continue
to arise in relation to other developing biotechnologies. Thus,
transparent regulation and a clear regulatory path forward will become
more pressing as the FDA’s current regulatory scheme will likely be an
obstacle for other medical innovations as science moves towards
targeting genes as a method of curing or preventing disease.
I. ADVANCED ASSISTED REPRODUCTIVE TECHNOLOGIES:
COMBINING GENETIC MODIFICATIONS WITH IN VITRO FERTILIZATION
Advanced assisted reproductive technologies, such as cytoplasmic
transfer and mitochondrial transfer involve the use of in vitro
fertilization and genetic material from a donor.
In vitro fertilization (IVF) is a procedure by which a female egg is
23 See Ewen Callaway, UK Scientists Gain Licence to Edit Genes in Human Embryos,
NATURE (Feb. 1, 2016), http://www.nature.com/news/uk-scientists-gain-licence-to-edit-genesin-human-embryos-1.19270; see also John Cohen, Round One of CRISPR Patent Legal Battle
Goes to the Broad Institute, SCIENCE (Feb. 15, 2017, 2:30 PM), http://www.sciencemag.org/
news/2017/02/round-one-crispr-patent-legal-battle-goes-broad-institute; Antonio Regalado,
Engineering the Perfect Baby, MIT TECH. REV. (Mar. 5, 2015), https://
www.technologyreview.com/s/535661/engineering-the-perfect-baby; Questions and Answers
About CRISPR, BROAD INST., https://www.broadinstitute.org/what-broad/areas-focus/projectspotlight/questions-and-answers-about-crispr (last visited Feb. 27, 2018) (noting that “[i]n
January 2013, the Zhang lab” at the Broad Institute and MIT “published the first method to
engineer CRISPR to edit the genome in mouse and human cells”). The terms “gene editing”
and “genome editing” are used interchangeably in the literature when describing CRISPR-Cas9.
See What Are Genome Editing and CRISPR-Cas9?, U.S. NAT’L LIBR. MED. (Feb. 20, 2018),
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting (“Genome editing (also called
gene editing) is a group of technologies that give scientists the ability to change an organism’s
DNA.”).
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fertilized outside the womb by male sperm, with the intent that the
resulting zygote will later be transplanted into the female
reproductive system of either the intended mother or another
woman who is serving as a surrogate. 24

A cell essentially contains three parts: cytoplasm, nucleus, and
mitochondria. 25 The nucleus, which is the center of the cell, is
surrounded by cytoplasm. 26 Mitochondria are located in the cytoplasm
of the cell. 27
With cytoplasmic transfer, donor genetic material (from the
cytoplasm of an egg cell) is used to improve fertility outcomes. 28 In
contrast, with mitochondrial transfer, donor genetic material
(specifically mitochondria) is used in order to prevent the maternal
transmission of some genetic diseases caused by defective mitochondria
such as muscular dystrophy and heart and liver conditions. 29 Preimplantation genetic diagnosis is insufficient to prevent the maternal

24 CHARLES P. KINDREGAN, JR. & MAUREEN MCBRIEN, ASSISTED REPRODUCTIVE
TECHNOLOGY: A LAWYER’S GUIDE TO EMERGING LAW AND SCIENCE 91 (2d ed. 2012).
25 See Charlotte Pritchard, The Girl with Three Biological Parents, BBC NEWS (Sept. 1,
2014), http://www.bbc.com/news/magazine-28986843 (defining the components of a cell as:
“Nucleus: Where the majority of our DNA is held - this determines how we look and our
personality[;] Mitochondria: Often described as the cell’s factories, these create the energy to
make the cell function[;] Cytoplasm: The jelly like substance that contains the nucleus and
mitochondria[.]”).
26 Id.
27 Id.
28 See GEOFF WATTS ET AL., NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR
THE PREVENTION OF MITOCHONDRIAL DNA DISORDERS: AN ETHICAL REVIEW 1, 36 (2012),
http://nuffieldbioethics.org/wp-content/uploads/2014/06/Novel_techniques_for_the_
prevention_of_mitochondrial_DNA_disorders_compressed.pdf. In cytoplasmic transfer, eggs
are obtained from both the intended mother and an egg donor, and cytoplasm from a healthy
egg is injected into the intended mother’s egg. Id. Children born as a result of cytoplasmic
transfer are genetically related to their intended mother and intended father; these children also
have “an additional mitochondrial genetic connection to a second woman provided by an
injection of her cytoplasm.” Id. at 70.
29 See, e.g., NAT’L ACADS. OF SCIS., ENG’G & MED., MITOCHONDRIAL REPLACEMENT
TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 1, 20–23 (2016) [hereinafter
MITOCHONDRIAL REPLACEMENT TECHNIQUES]. Using mitochondrial transfer, scientists replace
an intended mother’s defective mitochondria with mitochondria from a healthy female donor
either in the intended mother’s egg before in vitro fertilization occurs or in a fertilized embryo
after in vitro fertilization has occurred. The healthy embryo is then implanted into the intended
mother. There are three ways of acquiring diseases that affect mitochondria, one of which is
inheriting a harmful mitochondrial mutation from the mother. Id. at 4; see also Gráinne S.
Gorman et al., Mitochondrial Donation—How Many Women Could Benefit?, 372 NEW ENG. J.
MED. 885 (2015); Ian Sample, Three-Person IVF: UK Government Backs Mitochondrial
Transfer, GUARDIAN (June 28, 2013), http://www.theguardian.com/science/2013/jun/28/ukgovernment-ivf-dna-three-people; WATTS ET AL., supra note 28, at 21 (noting that
mitochondria generate energy for the cell, and mitochondrial mutations tend to have “the most
impact on organs of the body with a relatively high need for energy” such as the “brain, heart,
kidneys and major muscle groups” and thus, defective mitochondria tend to affect major
organs and a number of symptoms can result including blindness, deafness, and organ failure).
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transmission of mitochondrial disease. 30 While defective mitochondria
are maternally transmitted, male and female children are at equal risk of
developing mitochondrial disease, so selecting only male embryos
would not prevent the development of mitochondrial disease. 31
Because both cytoplasmic transfer and mitochondrial transfer
involve the transfer of a donor’s genetic material, both techniques would
result in an inheritable genetic modification that would be passed on to
future generations. 32 Nuclear DNA contains approximately 20,000 to
30,000 genes, accounting for approximately 99.9% of all of humans’
genes; the remaining percentage is made of the thirty-seven genes
contained in mitochondrial DNA. 33 As a result, with mitochondrial
transfer, only 0.1% of the healthy child’s DNA is different from that of
his or her parents. 34 The value of 0.1%, which is often cited in press
accounts, is actually rounded up: “mitochondrial DNA represents less
than 0.054 per cent of the total DNA . . . .” 35 This change in
mitochondrial DNA, in the view of some commentators, constitutes a
“modification of [the] human germline” which is a source of ethical

30 See WATTS ET AL., supra note 28, at 23 (“In reproduction, a small number of the woman’s
mitochondria are selected to populate all the cells of the resulting child in much greater
numbers, a phenomenon known as the ‘mitochondrial bottleneck.’” Thus, a woman with a
small proportion of defective mitochondria can pass a larger proportion of those mutant
mitochondria on to her children. “Patients with the symptoms of mitochondrial DNA disorders
are therefore likely to have mutations either in a high proportion of their mitochondria
(heteroplasmy) in the affected tissues or, when viable, in all of the mitochondria
(homoplasmy). . . .Generally, as the proportion of mutated mitochondria becomes higher,
progressively more severe symptoms will result.”); see also Daniel Paull et al., Nuclear Genome
Transfer in Human Oocytes Eliminates Mitochondrial DNA Variants, 493 NATURE 632, 632
(2013) (“[A]n unaffected carrier of a [mitochondrial DNA] mutation may have an affected
child. Although prenatal genetic diagnosis can select embryos with a reduced mutation load,
variation between blastomeres in single embryos limits the effectiveness of such screening, and
considerable levels of mutant [mitochondrial DNA] can remain, resulting in a carrier.” (citing
L.M. Cree et al., A Reduction of Mitochondrial DNA Molecules During Embryogenesis Explains
the Rapid Segregation of Genotypes, 40 NATURE GENETICS 249 (2008))).
31 See MARK S. FRANKEL & BRENT T. HAGEN, NUFFIELD COUNCIL ON BIOETHICS, GERMLINE
THERAPIES 11 (2011), http://nuffieldbioethics.org/wp-content/uploads/Germline_therapies_
background_paper.pdf.
32 See Transcript of Center for Biologics Evaluation and Research, Food and Drug
Administration, Cellular, Tissue, and Gene Therapies Advisory Committee Meeting #59 (Feb.
25, 2014) [hereinafter Meeting #59 Transcript], https://wayback.archive-it.org/7993/
20170113010701/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting
Materials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisory
Committee/UCM426293.pdf; Erik Parens & Eric Juengst, Inadvertently Crossing the Germ Line,
292 SCIENCE 397 (Apr. 20, 2001) (characterizing the transfer of mitochondrial DNA as a “side
effect” of cytoplasm transfer).
33 See WATTS ET AL., supra note 28, at 18–19.
34 See id. at 19.
35 Sally Davies, Sally Davies: Why I Back “Three-Parent Babies” Law, TELEGRAPH (Feb. 3,
2015, 6:00 AM), http://www.telegraph.co.uk/news/science/science-news/11385721/SallyDavies-Why-I-back-three-parent-babies-law.html (Professor Dame Sally Davies is the U.K.’s
Chief Medical Officer and Chief Scientific Adviser to the Telegraph.).
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opposition to advanced assisted reproductive technologies. 36 The
debatable definition of a germline modification will be discussed in Part
III.
AARTs transfer mitochondrial DNA and not nuclear DNA.37
Mitochondrial DNA “is not part of the nuclear DNA, which determines
our personal characteristics and traits such as personality, hair[,] and
eye colour.” 38 Because nuclear DNA determines inherited appearancerelated traits such as eye color, hair color, and height, and AARTs only
affect mitochondrial DNA, a child born as a result of the use of an
advanced assisted reproductive technology would still look like his or
her parents. 39
Cytoplasmic transfer, an advanced assisted reproductive
technology, has been used in the United States, but is no longer available
in the United States after researchers received “Untitled Letters” from
the FDA on July 6, 2001. 40 When researchers appeared at an FDA
Advisory Committee meeting after receiving the letters, a total of “at
least 23 children” had been born in the United States using cytoplasmic
transfer. 41
Mitochondrial transfer has not been approved for clinical use in
humans in the United States even though thousands of women (and
their children) could benefit from this disease-preventing technology. 42
36 See FRANKEL & HAGEN, supra note 31, at 1, 5–6 (citations omitted) (“Because [nuclear
DNA and mitochondrial DNA are not the same], some researchers and clinicians restrict the
definition of germline modification to modification of [nuclear DNA] alone. However, many
argue that [mitochondrial DNA] modification does indeed amount to germline modification.”
(citations omitted)); see also Meeting #59 Transcript, supra note 32, at 118 (A germline
modification such as that which would occur as a result of mitochondrial transfer would not
only result in a mother having a healthy child, but also that child having mutation-free eggs;
thus, the transmission of defective mitochondria would end in that family.).
37 See Davies, supra note 35.
38 Id.
39 See Kenan Malik, Opinion, The Three-Parent Baby’s First Step, N.Y. TIMES (Feb. 22,
2015), http://www.nytimes.com/2015/02/23/opinion/the-three-parent-babys-first-step.html?_
r=0; see also Andrew Sparrow, MPs Back Mitochondrial Donation Law By Majority of 254:
Politics Live Blog, GUARDIAN: POLITICS (Feb. 3, 2015, 12:45 PM), http://www.theguardian.com/
politics/blog/live/2015/feb/03/william-hagues-speech-on-english-votes-for-english-laws-evelpolitics-live-blog (citing Labour Party politician Liz McInnes, a former biochemist with the
National Health Service, who voted in favor of mitochondrial transfer).
40 See discussion infra Part II (discussing these Untitled Letters); see also Holly Firfer, How
Far Will Couples Go to Conceive?, CNN (June 17, 2004, 6:44 AM), http://www.cnn.com/2004/
HEALTH/03/12/infertility.treatment/index.html; supra notes 4–5 and accompanying text
(discussing the FDA’s use of Warning Letters and Untitled Letters).
41 Meeting #32 Transcript, supra note 8, at 46.
42 See Gorman et al., supra note 29, at 886 (noting that, as per 2012 data, 12,423 women of
child-bearing age in the United States could possibly pass a mitochondrial disease on to their
offspring); see also James Gallagher, UK Approves Three-Person Babies, BBC NEWS (Feb. 24,
2015), http://www.bbc.com/news/health-31594856; Tavernise, supra note 13 (“Dr. Dorsa said
the university still has not decided whether to formally ask the F.D.A. for permission to move
forward with clinical trials.”). As of July 12, 2016, the University still had not submitted an
investigational new drug application to the FDA.
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After an extensive public consultation, described in Part IV, and the
approval of regulatory amendments by Parliament, human clinical trials
involving mitochondrial transfer are ongoing in the United Kingdom
(U.K.). 43 The science underlying advanced assisted reproductive
technologies has been explained in newspaper articles, parliamentary
briefings, and public meetings; in other words, the science is not that
difficult to understand, but as will be explained in Part III, the ethical
opposition, especially in the United States, is inevitable. 44
II. THE REGULATION OF ASSISTED REPRODUCTIVE TECHNOLOGY IN
THE UNITED STATES
Although there are laws that apply to the use of assisted
reproductive technology, the industry is often characterized as
“unregulated,” “minimally regulated,” 45 or “self-regulated” when
compared to other industries. 46 In the United States, assisted
reproductive technology is generally governed by state law with the
exception of one federal law, the Fertility Clinic Success Rate Act. 47
With only one federal law addressing the regulation of assisted
reproductive technology, the federal government has been described as
“essentially silent.” 48 Under the 1992 Fertility Clinic Success Rate and
Certification Act, all clinics using assisted reproductive technology
techniques must report success rate data to the Centers for Disease
Control and Prevention on an annual basis. 49 During the congressional
43 See Gorman et al., supra note 29, at 886 (noting that, in 2015, 2,473 women of childbearing age in the United Kingdom could possibly pass a mitochondrial disease onto their
offspring); see also Gallagher, supra note 42.
44 See Gallagher, supra note 42; see also Mitochondrial Replacement, HUMAN FERTILISATION
& EMBRYOLOGY AUTH., http://web.archive.org/web/20150912083629/http://hfea.gov.uk/
6896.html (last updated July 9, 2015); PREVENTING MITOCHONDRIAL DISEASE, supra note 12.
45 Goodwin, supra note 1.
46 See Martha M. Ertman, What’s Wrong with a Parenthood Market?: A New and Improved
Theory of Commodification, 82 N.C. L. REV. 1, 15–16 (2003) (discussing the lack of regulation
of the “parenthood market”); Jane Gitschier, The Ethics of Our Inquiry: An Interview with Hank
Greely, 11 PLOS GENETICS (Nov. 6, 2014) (quoting an interview with Hank Greely, who
characterized assisted reproductive technology as “[a]lmost entirely” unregulated in the United
States); Debora Spar & Anna M. Harrington, Building a Better Baby Business, 10 MINN. J.L. SCI.
& TECH. 41 (2009) (discussing the lack of regulation of the “fertility market,” which is the
market for the sale of gametes for use in assisted reproduction); Sonia M. Suter, Giving in to
Baby Markets: Regulation Without Prohibition, 16 MICH. J. GENDER & L. 217, 231 (2009); Chan
& Collins, supra note 1, at 507–08.
47 See Michele Goodwin, A View from the Cradle: Tort Law and the Private Regulation of
Assisted Reproduction, 59 EMORY L.J. 1039, 1071–72, 1079 (2010).
48 SPAR, supra note 1, at 51.
49 See 42 U.S.C. §§ 263a-1–7 (2012) (codifying the Fertility Clinic Success Rate Act); see also
The Fertility Clinic Success Rate and Certification Act, CENTERS DISEASE CONTROL, http://
www.cdc.gov/art/nass/policy.html (last updated Feb. 8, 2017) (citing to Pub. L. No. 102-493,
106 Stat. 3146 (1992)). Also, while the National Institutes of Health (NIH) arise in discussions
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debate preceding the enactment of the Fertility Clinic Success Rate and
Certification Act, “the FDA was never mentioned . . . as having
jurisdiction over fertility clinic procedures.” 50
State law generally does not restrict the mechanics of assisted
reproductive technology, such as how many embryos can be implanted
or how many times the reproductive tissue of one donor can be used.51
States, and not the FDA, also regulate the practice of medicine through
the licensing of the medical personnel who would perform procedures
involving assisted reproductive technology. 52 Other than these
provisions, state regulation of assisted reproductive technology is
“limited.”53 Moreover, professional organizations such as the American
Society for Reproductive Medicine issue guidelines for providers of

related to embryos and research funding, the NIH, while an operating division of the U.S.
Department of Health and Human Services, does not have a role in the regulation of assisted
reproductive technology. Instead, the NIH’s role in the development of assisted reproductive
technology is very limited as the agency specifically does not fund scientific research that
modifies the human germline but does not regulate its legality. See NAT’L INSTS. OF HEALTH,
DEP’T HEALTH & HUMAN SERVS., NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT
OR SYNTHETIC NUCLEIC ACID MOLECULES (NIH GUIDELINES) (Apr. 2016), https://
osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.html#_Toc446948304; Francis S. Collins,
Statement on NIH Funding of Research Using Gene-Editing Technologies in Human Embryos,
NAT’L INSTITUTES HEALTH (Apr. 28, 2015), https://www.nih.gov/about-nih/who-we-are/nihdirector/statements/statement-nih-funding-research-using-gene-editing-technologies-humanembryos.
50 See Gregory J. Rokosz, Human Cloning: Is the Reach of FDA Authority Too Far a Stretch?,
30 SETON HALL L. REV. 464, 503 n.201 (2000) (citing Elizabeth C. Price, Does the FDA Have
Authority to Regulate Human Cloning, 11 HARV. J.L. & TECH. 619, 631 (1998)).
51 See Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregulated
Biomedical Innovation, 55 FLA. L. REV. 603, 615–16 (2003); Michael Ollove, States Aren’t Eager
to Regulate Fertility Industry, USA TODAY, http://www.usatoday.com/story/news/nation/2015/
03/18/pew-stateline-assisted-reproduction/24984249 (last updated Mar. 26, 2015, 3:22 PM).
52 See Marion Abecassis, Artificial Wombs: “The Third Era of Human Reproduction” and
the Likely Impact on French and U.S. Law, 27 HASTINGS WOMEN’S L.J. 3, 10 (2016) (explaining
that states regulate the practice of medicine “through licensing of practitioners, including
suspension and revocation of licenses in instances of malpractice”); see also LASIK: FDA’s Role,
U.S. FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/ProductsandMedical
Procedures/SurgeryandLifeSupport/LASIK/ucm061319.htm (last updated Jan. 18, 2018);
Rokosz, supra note 50, at 491 n.147 (quoting University of Virginia Law School professor
Richard Merrill, who stated that “the FDA is not supposed to regulate the practice of
medicine”).
53 See Hillary B. Alberta et al., Risk Disclosure and the Recruitment of Oocyte Donors: Are
Advertisers Telling the Full Story?, 42 J.L. MED. & ETHICS 232, 235 (2014); Chan & Collins, supra
note 1, at 507 (“Currently, regulation over reproductive technology by the state and federal
government is limited. The fertility industry mostly self regulates through nonbinding
guidelines and suggested ethical practices, though there are various physician licensing
requirements.” (citations omitted)). For more on state law applying to assisted reproductive
technology, such as statutes related to fraud, medical malpractice, and consumer protection, see
SPAR, supra note 1, at 51; Noah, supra note 51, at 615–16. See also John A. Robertson,
Commerce and Regulation in the Assisted Reproduction Industry, in BABY MARKETS: MONEY
AND THE NEW POLITICS OF CREATING FAMILIES 191, 203 (Michele Bratcher Goodwin ed.,
2010).
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assisted reproductive technology to follow. 54
States also decide how the parentage of children who are conceived
through assisted reproductive technology will be assigned. 55 Because
individual states have their own laws addressing family law and estate
law, the legal consequences of assisted reproductive technology such as
inheritance and the legality of surrogacy and other methods of family
formation are similarly addressed “on a state-by-state basis . . . .” 56 The
next Section of the Article explains why the characterization of the
regulatory environment surrounding assisted reproductive technology
as “sparse” is inaccurate when one analyzes the regulation of advanced
assisted reproductive technologies. 57
A.

The Concept of Subterranean Regulation

In this Article, I characterize the overlooked regulatory program
that the U.S. Food and Drug Administration uses to regulate advanced
assisted reproductive technologies as “subterranean regulation.” This
concept fits within the larger administrative law scholarship on agency
“soft law.” 58 Within the context of administrative law, much has been
written about the concept of “regulating by guidance” and other
informal methods of regulating in which an agency uses informal
documents to affect the actions of regulated entities. 59 Beyond guidance
54 See Chan & Collins, supra note 1, at 507 (“Currently, regulation over reproductive
technology by the state and federal government is limited. The fertility industry mostly self
regulates through nonbinding guidelines and suggested ethical practices, though there are
various physician licensing requirements.” (citation omitted)). But see CAHN, supra note 1, at
63, 192–93 (“As the CDC emphasizes, however, the federal government does not provide any
oversight of these programs, and their standards vary.”).
55 See generally KINDREGAN & MCBRIEN, supra note 24.
56 Blake, supra note 16, at 372. The literature related to mitochondrial transfer focuses on
the legal impacts of the technology on the genetically based parentage scheme in the United
States and the impacts of the technology on trusts and estate law. See Daar, supra note 16; see,
e.g., Padmini Cheruvu, Three-Parent IVF and Its Effect on Parental Rights, 6 HASTINGS SCI. &
TECH. L.J. 73 (2014); Yehezkel Margalit et al., The New Frontier of Advanced Reproductive
Technology: Reevaluating Modern Legal Parenthood, 37 HARV. J.L. & GENDER 107, 128 (2014);
see also Steve P. Calandrillo & Chryssa V. Deliganis, In Vitro Fertilization and the Law: How
Legal and Regulatory Neglect Compromised a Medical Breakthrough, 57 ARIZ. L. REV. 311, 330
(2015) (characterizing state regulation of assisted reproductive technology as similarly
“undeveloped” in comparison to federal regulation of assisted reproductive technology).
57 See JUDITH DAAR, REPRODUCTIVE TECHNOLOGIES AND THE LAW 682 (2d ed. 2013)
(referring to the Fertility Clinic Success Rate of 1992 as “sparse law” when observing, “[t]his
sparse law in the U.S. can be contrasted with comprehensive regulatory schemes in place in
other countries”).
58 Wu, supra note 19, at 1843–44; see Lars Noah, Governance by the Backdoor:
Administrative Law(Lessness?) at the FDA, 93 NEB. L. REV. 89, 92 n.9 (2014) (“Guidance
documents represent a form of ‘soft law.’” (quoting Jacob E. Gersen & Eric A. Posner, Soft Law:
Lessons from Congressional Practice, 61 STAN. L. REV. 573, 576–77 (2008))); Noah, supra note
19, at 874.
59 See M. Elizabeth Magill, Agency Choice of Policymaking Form, 71 U. CHI. L. REV. 1383,
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documents, some scholarship has focused on methods that
administrative agencies use to “threaten” compliance. 60 Subterranean
regulation could be classified as one of these methods of informal
regulation; however, one notable difference between subterranean
regulation and other forms of agency “threats” is that the scholarship on
administrative agency threats often does not direct a significant amount
of focus to the possibility that administrative agency threats are being
issued to industries that are not at all within the agency’s jurisdiction.
Subterranean regulation is characterized by a lack of jurisdiction in
addition to other procedural weaknesses. 61 First, subterranean
regulation occurs in a regulatory space in which the administrative
agency, here, the FDA, has not shown that it has jurisdiction over these
techniques in the first place. 62 Thus, while the scholarship on agency
threats tends to focus on agency threats to “regulated entities” or entities
that are not currently regulated but clearly fall within the agency’s
jurisdiction, industries targeted by subterranean regulation are
threatened in the absence of a regulatory basis for that threat. 63 As
discussed below, this jurisdictional defect in the subterranean regulation
of AARTs stems partially from the fact that the FDA has similarly not
cited to any statutory provisions that provide its jurisdiction as
evidenced by the Agency’s letters issued on July 6, 2001, and subsequent
regulatory actions and the fact that AARTs do not fit within the larger
categories of products regulated by the FDA.
Second, procedurally, subterranean regulation occurs in a manner
that is different from the standard process that the Agency uses. The
FDA issues Untitled Letters and Warning Letters to violators of federal

1441 (2004) (“Finally, in an example drawn from contemporary judicial decisionmaking, courts
appear to be increasingly concerned about the oft-repeated charge that agencies are ‘regulating
by guidance’—that is, relying on interpretive rules or policy statements instead of legislative
rules to effectuate their policy judgments.” (citing J.B. Ruhl & James Salzman, Mozart and the
Red Queen: The Problem of Regulatory Accretion in the Administrative State, 91 GEO. L.J 757,
781–82 (2003))); see also Robert A. Anthony, Interpretive Rules, Policy Statements, Guidances,
Manuals, and the Like–Should Federal Agencies Use Them to Bind the Public?, 41 DUKE L.J.
1311, 1312 (1992) (“To use such nonlegislative documents to bind the public violates the
Administrative Procedure Act (APA) and dishonors our system of limited government.”).
60 Wu, supra note 19, at 1848–54.
61 This Section provides an overview of subterranean regulation whereas the next Section,
Section II.B, provides detailed specifics on the operation of the concept.
62 See discussion infra Section II.B.2.
63 Wu, supra note 19, at 1843, 1848–54 (“Regulated entities that are unhappy with a de facto
regime can and do test the threats, forcing the agency to use its more formal powers and
therefore invoke judicial review.”) (providing examples of industries in which “threats” have
been used, notably that of the Federal Communications Commission to broadband providers);
see also Noah, supra note 19, at 874 (“As used in this Article, administrative ‘armtwisting’ refers
to a threat by an agency to impose a sanction or withhold a benefit in hopes of encouraging
‘voluntary’ compliance with a request that the agency could not impose directly on a regulated
entity.”).
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law regularly. 64 These letters usually have specific citations to statutory
provisions when issued in the context of food, drugs, and other
regulated products, along with explanations of how those provisions
apply to the addressee’s actions or products. 65 In other words, in these
letters, the FDA usually identifies the regulated entities’ actions and then
explains how those actions violate a specific statutory provision.
However, the Untitled Letters addressing advanced assisted
reproductive technologies are not as specific as the FDA’s other Untitled
Letters. Instead, the letters that the Agency uses to target AARTs are
characterized by not only brevity and citations to guidance documents
that may or may not apply to AART providers, but also by a lack of
specificity. Yet at the same time, these letters are official agency
communications that are assertions of wrongdoing. The content of the
FDA’s July 6, 2001 letter to AART providers is located in Appendix A
and examples of the FDA’s standard practices when issuing Untitled
and Warning Letters are in Appendices B to D for comparison.
Third, subterranean regulation is difficult to find. While the
content of the July 6, 2001 letters is posted online, the addressees are
not. The addressee line simply states, “Dear Sponsor/Researcher” and
there is no additional identifying information. Furthermore, I submitted
a FOIA request to obtain the list of addressees; however, the Agency
stated that it “did not locate an admin file” for the letter, therefore, it
was unable to provide me with a list of addressees. 66 As a result, it is
impossible to officially determine how many of these letters were sent or
to whom they were sent. By reviewing primary sources, including
transcripts and media accounts, I was able to ascertain some of the
addressees as they spoke about receiving “the letter,” but it is still
impossible to ascertain all of the recipients. 67 Subsequently in 2013, for
example, the FDA carried out a similar approach to regulating the
64 For examples of these letters, see infra Appendices C–D. See also Warning and Untitled
Letters, supra note 4 (describing the FDA’s use of Untitled Letters and Warning Letters).
65 See, e.g., Letter from Robert A. Sausville, Dir. Div. of Case Mgmt., U.S. Food & Drug
Admin., to Samuel Simons, Regulatory Manager, Protein Scis. Corp. (Mar. 12, 2015),
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory
Information/ComplianceActivities/Enforcement/UntitledLetters/UCM443161.pdf (“Therefore,
this material misbrands Flublok under sections 502(a) and 201(n) of the Act, 21 U.S.C. § 352(a)
and § 321(n), and FDA implementing regulations, Cf. 21 CFR 202.1(e)(6)(i) and (e)(7)(viii).”);
Letter from Ann Simoneau, Dir. Office of Compliance & Enf’t, U.S. Food & Drug Admin., to
George Katsafados (Sept. 29, 2014), http://www.fda.gov/ICECI/EnforcementActions/Warning
Letters/2014/ucm416552.htm (“Under section 201(rr) of the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C. § 321(rr)), as amended by the Family Smoking Prevention and
Tobacco Control Act (Tobacco Control Act), these products are tobacco products because they
are made or derived from tobacco and intended for human consumption. Certain tobacco
products, including cigarette tobacco and roll-your-own tobacco, are subject to FDA
jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)).”).
66 See Email from Ashlee Eswara to author, supra note 6.
67 See Meeting #32 Transcript, supra note 8, at 77.
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actions of an American company providing a new fertility method; that
letter was also not posted online by the FDA, and I was only able to
obtain it through a FOIA request. 68 In contrast, the example of a “secret
letter [sent] to various retailers and manufacturers of new ‘bamboo
clothing,’” cited in Tim Wu’s Agency Threats, was accompanied by a
footnote that linked to a PDF of the list of recipients, thus implying that
secret letters sent by other administrative agencies are at least
traceable. 69
Fourth, subterranean regulation has a “chilling effect” on research.
Even though the FDA’s subterranean letters do not provide a clear basis
for the Agency’s jurisdiction, as official statements of wrongdoing, these
issuances have a chilling effect on research. 70
B. Thwarted Research and Medical Advancement: The Impacts of
the FDA’s Subterranean Assertions of Jurisdiction over Advanced Assisted
Reproductive Technologies
The FDA has regulated cloning and advanced assisted reproductive
technologies through letters as opposed to clear, targeted regulations.
Cloning does not fall within this Article’s definition of advanced assisted
reproductive technologies since it does not operate in the same manner
as human reproduction which involves at least two individuals (i.e., an
intended mother and an intended father). 71

68 See discussion infra Part IV regarding the FOIA Request 2016-4882 and the shareholder
lawsuit related to OvaScience’s AUGMENT technology.
69 See Wu, supra note 19, at 1845.
70 For a discussion of the “chilling effect” in the context of abortion rights, see Brandice
Canes-Wrone & Michael C. Dorf, Measuring the Chilling Effect, 90 N.Y.U. L. REV. 1095, 1096–
98 (2015). “Chilling effect” is a concept that commonly arises in First Amendment
jurisprudence. Id.
71 For the full contents of the letter, see infra Appendix B. But see Cloning, NAT’L HUMAN
GENOME RES. INST., https://www.genome.gov/25020028/cloning-fact-sheet/#al-8 (last updated
Mar. 21, 2017) (“Reproductive cloning would present the potential of creating a human that is
genetically identical to another person who has previously existed or who still exists. This may
conflict with long-standing religious and societal values about human dignity, possibly
infringing upon principles of individual freedom, identity and autonomy. However, some argue
that reproductive cloning could help sterile couples fulfill their dream of parenthood. Others
see human cloning as a way to avoid passing on a deleterious gene that runs in the family
without having to undergo embryo screening or embryo selection. Therapeutic cloning, while
offering the potential for treating humans suffering from disease or injury, would require the
destruction of human embryos in the test tube. Consequently, opponents argue that using this
technique to collect embryonic stem cells is wrong, regardless of whether such cells are used to
benefit sick or injured people.”); see also Human Cloning: How Close Is It?, PBS, https://
www.pbs.org/wgbh/pages/frontline/shows/fertility/etc/cloning.html (last visited Feb. 22, 2018).
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Letters as Assertions of Wrongdoing

In 1998, the FDA sent a “Dear Colleague Letter” to institutional
review boards in the United States asserting its jurisdiction over human
reproductive cloning in reaction to media reports indicating that
scientists were “contemplating” using human cloning. 72 This letter
noted that clinical research on human cloning “to create a human
being” could only proceed while an investigational new drug application
was in effect. 73 In 2001, the FDA shifted its focus to advanced assisted
reproductive technologies, sending letters to sponsors and researchers
on July 6, 2001 that informed these individuals and entities that the
FDA had jurisdiction over these technologies, such as cytoplasmic
transfer. 74 The FDA has added mitochondrial transfer, an advanced
assisted reproductive technology, to the non-exhaustive list of assisted
reproductive technologies that require FDA pre-approval. 75
72 Issues Raised by Human Cloning Research: Hearing Before the H. Subcomm. on Oversight
and Investigations of the Comm. on Energy and Commerce, 107th Cong. 78–81 (2001)
(statement of Kathryn C. Zoon, Dir. of Ctr. for Biologics Evaluation & Research, U.S. Food &
Drug Admin.) [hereinafter Statement of Kathryn C. Zoon]; Stuart L. Nightingale, Letter About
Human Cloning, U.S. FOOD & DRUG ADMIN. (Oct. 26, 1998), http://www.fda.gov/Science
Research/SpecialTopics/RunningClinicalTrials/ucm150508.htm. The list of addressees is not
included online for this letter either. Under the U.S. Department of Health and Human Services
(HHS) regulations, “45 CFR part 46, subpart E, [HHS] require[s] all IRBs to register with HHS
if they will review human subjects research conducted or supported by HHS and are to be
designated under an assurance of compliance approved for federalwide use (i.e., an FWA) by
OHRP.” IRB Registration Process Frequently Asked Questions (FAQs), HHS.GOV, http://
www.hhs.gov/ohrp/register-irbs-and-obtain-fwas/irb-registration/irb-registration-faq/
index.html# (last visited Mar. 2, 2018). Thus, those pursuing research not supported by the U.S.
Department of Health and Human Services, as cloning would not be, would possibly not be
registered with the U.S. Department of Health and Human Services and thus, not receive the
letter.
73 See Nightingale, supra note 72.
74 See Appendix A (providing the FDA’s Letter to Sponsors/Researchers, on the subject of
cytoplasmic transfer); see also General Responsibilities of Sponsors, 21 C.F.R. § 312.50 (2016)
(explaining that “sponsor” in FDA terminology signifies that an individual or entity has a
pending investigational new drug application before the FDA); Meeting #32 Transcript, supra
note 8, at 47 (“FDA had concerns about whether we understood all the ramifications of this
procedure and whether we understood its safety in particular, and reacted by sending letters to
practitioners who were identified by publications on ooplasm [cytoplasm] transfer or by
advertisements offering the procedure. We advised practitioners that we would now require the
submission of an investigational new drug application, or IND, to the agency and its
subsequent review to continue to treat new patients.”).
75 See FDA Regulation of Human Cells, supra note 12 (listing “HUMAN CELLS USED IN
THERAPY INVOLVING THE TRANSFER OF GENETIC MATERIAL (cell nuclei, oocyte
nuclei, mitochondrial genetic material in ooplasm, genetic material contained in a genetic
vector)” as products that are “[r]egulated under Section 351 of the [Public Health Service] Act
and/or the [Food, Drug & Cosmetic] Act” without explaining how the communicable disease
provision of the Public Health Service Act “and/or” the Food, Drug, and Cosmetic Act applies
to these products); see also discussion infra Part II (explaining that the application of the FDA’s
Human Tissue Regulations to human reproductive tissue is counterintuitive and
contradictory).
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Lack of Jurisdiction

The FDA’s July 6, 2001 letter to sponsors and researchers was the
first letter that the Agency sent regarding advanced assisted
reproductive technologies after decades of little involvement in the
broader field of assisted reproductive technology. 76 As noted in the
Introduction, the July 6, 2001 letter stated “[w]e want to advise you that
the Food and Drug Administration (FDA) has jurisdiction over human
cells used in therapy involving the transfer of genetic material by means
other than the union of gamete nuclei.” 77 The letter also listed five FDA
documents that provided “notice” of this jurisdiction; those documents
are analyzed in Section II.C. 78 Documents, however, do not provide
notice of jurisdiction, statutes do. Yet, the FDA failed to cite any specific
statutory provisions that would explain the basis for its jurisdiction over
advanced assisted reproductive technologies. Moreover, the FDA’s
broad reference to the Federal Food, Drug, and Cosmetic Act, a statute
of significant length, is insufficient, especially when compared to the
FDA’s usual practice.
The FDA’s July 6, 2001 letter provided a list of examples of “the
transfer of genetic material” and included cytoplasmic transfer in that
list. 79 The letter then stated “[t]he use of such genetically manipulated
cells (and/or their derivatives) in humans constitutes a clinical
investigation and requires submission of an Investigational New Drug
application (IND) to FDA,” although a later sentence in the letter noted
“[w]e can advise you whether or not your activities require submission
of an IND.” 80 Thus, not only was it counterintuitive that the FDA would
be asserting jurisdiction over a form of assisted reproductive technology
at all, but the letter itself contained contradictions.
Beyond the Agency’s failure to identify the source of its
jurisdiction, the natural counterargument to an assertion that an agency
does not have jurisdiction over a specific field or action is one that
addresses the issue of Chevron deference. 81 However, as will be
76 See discussion infra Section II.C (discussing the evolution of the FDA’s regulations from
not addressing in vitro fertilization to addressing advanced assisted reproductive technology).
77 See infra Appendix A. While the content of the letter is available on the FDA’s website,
the list of recipients is not. Similarly, a FOIA request revealed that the agency was unable to
find the file related to the letter; therefore, a list of sponsor/researchers who received the letter
is not available.
78 See infra Appendix A.
79 See infra Appendix A (examples listed were “cell nuclei (e.g., for cloning), . . . oocyte
nuclei, . . . ooplasm [cytoplasm], which contains mitochondrial genetic material, and . . . genetic
material contained in a genetic vector, transferred into gametes or other cells”).
80 See infra Appendix A.
81 While Chevron deference is often the first type of deference referred to in the context of
judicial review of agency decision-making, it is one of many types of deference. See Kevin M.
Stack, Purposivism in the Executive Branch: How Agencies Interpret Statutes, 109 NW. U. L. REV.
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explained in Part III, ethical views are not an area in which agencies are
entitled to Chevron deference.
3.

Obfuscation of the Evidence of Agency Action

Furthermore, it is difficult to effectively challenge agency action
when one does not know the scope of that action. Other scholars of
administrative law have criticized administrative agency processes for
issuing “non-substantive” rules, such as guidance documents. 82 I agree
with those criticisms of the shortcomings of the Administrative
Procedure Act’s application to those rules, including the lack of a
publicly available administrative record and the difficulty in challenging
those interpretative rules. 83 While non-substantive rules tend to be
guidance documents, subterranean regulation often exacerbates these
concerns as one can more easily find the content of guidance documents
than evidence of the agency’s subterranean regulation. The case of the
FDA’s regulation of AARTs indicates that absent a FOIA request and a
FOIA response that is wholly responsive to that request, the public does
not have comprehensive evidence of the content and the scope of the
Agency’s subterranean regulation thus rendering subterranean
regulation more problematic than other forms of agency soft law.
4.

“Chilling” Effects

The FDA’s letters to researchers also do not threaten enforcement
action; however, researchers perceive the letters as threatening. For
example, one recipient of a letter, Dr. Jamie Grifo, noted, “[w]hat was
threatening was they couldn’t give me a sense of what the consequences
would be . . . if I continued. They made it sound as if there would be
871, 878 n.22 (2015) (citing Chevron U.S.A. Inc. v. NRDC, 467 U.S. 837 (1984)). Under United
States v. Mead Corp., 533 U.S. 218, 234–35 (2001), if Chevron deference is not warranted, the
agency’s interpretation will be reviewed under Skidmore.
82 See Mark Seidenfeld, A Civic Republican Justification for the Bureaucratic State, 105
HARV. L. REV. 1511, 1561–62 (1992) (“The Administrative Procedure Act grants agencies
virtually complete discretion over the procedures they use to conduct informal adjudication
and to issue general statements of policy. . . . No requirements of an open record or public
discussion operate to constrain pure political influence or an agency’s pursuit of a private
agenda. For statements of policy, the usual justification for the absence of any required
procedures is the non-binding nature of such statements. From a civic republican perspective,
however, this justification is inadequate. Subsequent agency adjudicatory proceedings are
adversarial and hence probably will not cure the lack of opportunities for access and
deliberation. The adversarial nature of subsequent proceedings will be aggravated by the fact
that the agency has already committed itself to a position and may be reluctant to consider
seriously arguments to the contrary.”).
83 Id.
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recourse without saying it. I was very threatened . . . .” 84 Dr. Grifo’s work
actually involved a form of mitochondrial transfer called “pronuclear
transfer.” 85 Other addressees’ work, notably the work of Dr. Jacques
Cohen at the Saint Barnabas Medical Center and the work of physicians
at the Jones Institute of Eastern Virginia Medical School, involved the use
of cytoplasmic transfer. 86 These researchers stopped providing
cytoplasmic transfer in the United States after receiving the FDA’s letter. 87
While not mentioned by the FDA in its letters to researchers,
substantial penalties may result from violations of the Federal Food,
Drug, and Cosmetic Act and the Public Health Service Act. Penalties for
violating provisions of the Federal Food, Drug, and Cosmetic Act
include: imprisonment for up to one year, a $1,000 fine, or both for
first-time offenders; enhancements can increase the penalties to up to
three years imprisonment, a $10,000 fine, or both. 88 Similarly,
individuals who violate the Public Health Service Act face up to one year
in prison, up to a $100,000 fine (if no death has resulted from the
violation), or up to a $250,000 fine (if death has resulted from the
violation). 89 Thus, while there was no specific reference to criminal
penalties in the FDA’s letters to those working on advanced assisted
reproductive technologies, the specter of punishment still looms.
FDA employee statements in other venues reveal that the Agency is
troubled by the spread of advanced assisted reproductive technologies,
and in the case of cytoplasmic transfer, targeted the technology before
the results had been officially published. 90 Clinical use of cytoplasmic
Connor, supra note 12.
Id.
86 See Meeting #32 Transcript, supra note 8, at 46.
87 See id.
88 See 21 U.S.C. §§ 331, 333(a)(1)– 333(a)(2) (2012) (providing that if an individual violates
the Food, Drug, and Cosmetic Act “after a conviction of him under this [same] section has
become final, or commits such a violation with the intent to defraud or mislead, such person
shall be imprisoned for not more than three years or fined not more than $10,000, or both”).
89 See Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and
Tissue-Based Products, 69 Fed. Reg. 29785, 29788 (May 25, 2004) (also stating that
“organizational defendants [face] fines [that] range up to $200,000 [if no death has resulted
from the violation] and $500,000 [if death has resulted from the violation]”); see also Eligibility
Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products,
66 Fed. Reg. 5447, 5449 (Jan. 19, 2001) (The agency’s 2001 final rule stated “[a]uthority for
enforcement of section 361 of the PHS Act is provided by section 368 of the PHS Act (42 U.S.C.
271). Under section 368(a) of the PHS Act, any person who violates a regulation prescribed
under section 361 of the PHS Act may be punished by imprisonment for up to 1 year.
Individuals may also be punished for violating such a regulation by a fine of up to $100,000 if
death has not resulted from the violation or up to $250,000 if death has resulted (18 U.S.C. 3559
and 3571(c)).”).
90 See Meeting #32 Transcript, supra note 8, at 46–47 (Deborah Hursh, a cellular product
reviewer for the FDA stated at a 2002 Advisory Committee meeting that the agency “was
already considering action in the area of ooplasm transfer” at the time of Dr. Cohen’s
publication and that the agency felt that the use of cytoplasmic transfer was “beginning to
spread rapidly into clinical practice in the United States by 2001.” Dr. Hursh’s introduction also
84
85
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transfer in the United States ended after the FDA sent its 2001 letters. 91
This not only had a negative impact on medical advancement, but it also
reduced the incentive for physicians to undertake follow-up studies,
which already encounter difficulty in keeping patients. 92
Subterranean regulatory actions deter investment in the
biosciences. Even though assisted reproductive technology is usually
one industry that needs less investment due to the willingness of couples
to spend large sums of money to have a child genetically related to them,
funding is crucial. 93 For example, mitochondrial transfer, although an
advanced assisted reproductive technology, was developed by Dr.
Shoukhrat Mitalipov in a university laboratory. 94 As a university
researcher as opposed to a physician, Dr. Mitalipov would not
necessarily have patients willing to spend large sums of money to have a
genetically related child. 95 Federal funding is unavailable for embryo
research, which leaves private investment as a primary funding source
for human clinical studies. 96 However, investors also dislike unclear
regulatory frameworks: “Without a clear and rapid regulatory pathway,
Mitalipov says, he is unable to get the investment that he needs to
pursue clinical work [related to mitochondrial transfer].” 97
noted that three clinics had “published on this procedure and [the] FDA [was] able to find five
additional clinics that were advertising this procedure on the internet.” As a result, the agency
“advised practitioners that [it] would now require the submission of an investigational new
drug application, or IND, to the agency and its subsequent review to continue to treat new
patients.” (emphasis added)).
91 See June Carbone, Negating the Genetic Tie: Does the Law Encourage Unnecessary Risks?,
79 UMKC L. REV. 333, 348 (2010) (“The FDA’s assertion of jurisdiction was of dubious validity,
but since the clinic chose not to challenge it, the result has effectively shut down research and
use of the procedure in the United States.”); Meeting #32 Transcript, supra note 8, at 48–55
(providing the testimony of Dr. Susan Lazendorff of the Jones Institute for Reproductive
Medicine at the Eastern Virginia Medical School: “We were also looking at other things when
we were doing these studies and before we received our letter to stop doing them.”).
92 See Rachel Nolan, Behind the Cover Story: Kim Tingley on the Promise and Problems of
Three-Parent I.V.F., N.Y. TIMES (June 30, 2014, 5:00 AM), http://6thfloor.blogs.nytimes.com/
2014/06/30/kim-tingley-on-the-perplexity-and-promise-of-three-parent-i-v-f; Pritchard, supra
note 25 (“Due to a lack of funding, Cohen says, it hasn’t been possible to find out about how
any of the children like Alana who were born from cytoplasmic transfer are doing. But the St[.]
Barnab[a]s Institute is now starting a follow up study to check their progress.”); see also
Meeting #32 Transcript, supra note 8, at 123–24 (“So, we have been able to do follow-up in 13
of the 17 babies. However, more recently it is more likely that some of them will refuse further
investigations by us. This is not just this particular group. That is common for all infertility
follow-up, that you lose sight of these patients. Some of them will move and not even leave a
return address.”).
93 See SPAR, supra note 1.
94 See Tavernise, supra note 13.
95 See SPAR, supra note 1, at xiv.
96 See I. Glenn Cohen & Eli Y. Adashi, Preventing Mitochondrial DNA Diseases: One Step
Forward, Two Steps Back, 316 JAMA 273 (2016).
97 See David Cyranoski & Boer Deng, Stem-Cell Star Lands in Same Venture as Disgraced
Cloner, NATURE (Feb. 11, 2015), http://www.nature.com/news/stem-cell-star-lands-in-sameventure-as-disgraced-cloner-1.16907 (also noting “[t]he US-based scientist who first cloned

CARDOZO LAW REVIEW

1262

[Vol. 39:1239

The FDA’s unclear regulatory pathway has halted research at the
expense of follow-up studies on those already born as a result of
advanced assisted reproductive technologies, and it has also halted the
human clinical use of advanced assisted reproductive technologies.
Although more than fifteen years have passed since its assertion of
jurisdiction over cytoplasmic transfer, the FDA has provided no clear
explanation of the source of its jurisdiction over advanced assisted
reproductive technologies (which manifests through the requirement of
premarket approval) or why this divergence from the Agency’s “handsoff” treatment of conventional assisted reproductive technology is
justified.
C.

Drugs Versus Procedures: What the FDA Does and Does Not
Regulate

The FDA regulates food, drugs, tobacco products, pharmaceuticals,
medical devices, biological products, and cosmetics. 98 The FDA does not
regulate the practice of medicine, which means that while it regulates
the tools that physicians use in surgery (e.g., anesthesia, surgical
implants such as pacemakers, bone grafts, prosthetics, etc.) or in their
general practices (e.g., vaccines and prescription drugs), the FDA does
not regulate surgical techniques or diagnostic decisions. 99
The drugs and medical devices used by treatments categorized as
“assisted reproductive technology” are regulated by the FDA, but the
techniques used in assisted reproductive technology themselves are not
regulated by the FDA. The exception to this regulatory convention lies
in the FDA’s regulation of advanced assisted reproductive technologies.
For example, hormones, which are commonly referred to as “fertility
drugs” have been described as one of the “most basic components” of
assisted reproductive technology, and they are regulated by the FDA like
all pharmaceuticals. 100 Similarly, while sperm and eggs used in assisted
human embryonic stem cells is taking steps to apply his reproductive technology in China to
escape burdensome regulations and get funding. The result is a joint venture that brings stemcell star Shoukhrat Mitalipov of Oregon Health and Science University in Portland together
with disgraced cloner turned dog-clone entrepreneur, Woo Suk Hwang, although Mitalipov
says that the pair will not collaborate on research”).
98 See 21 U.S.C. §§ 341–46, 387a–r (2012); see also What Does FDA Regulate?, supra note
22.
99 See What Does FDA Regulate?, supra note 22. The term “bone grafts” refers to the bone
that is grafted and not the procedure itself.
100 See SPAR, supra note 1, at 35 (noting that the “most basic components” of the fertility
trade are “sperm, eggs, and hormones” and referring to what are commonly referred to as
hormonal treatments as “fertility drugs”); see also 21 U.S.C. §§ 201, 355; see, e.g., Infertility
Medications, AM. PREGNANCY ASS’N (May 16, 2017, 7:33 AM), http://americanpregnancy.org/
infertility/infertility-medications (providing an overview of many of the hormonal treatments
that are a part of fertility treatment in the United States).

2018]

SUBTERRANEAN REGULATION

1263

reproductive technology and advanced assisted reproductive technology
have, since 2001, been subject to the FDA’s communicable disease
requirements, analyzed below in Section II.D, the FDA does not
approve how those sperm and eggs are obtained, and the FDA does not
prohibit the use of all sperm and eggs in assisted reproductive
technology that can transmit communicable diseases. 101
New drugs may not be introduced into interstate commerce
“unless an approval of an application . . . is effective with respect to
[that] drug.” 102 Drugs are “articles intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease in man or other
animals; and . . . articles (other than food) intended to affect the
structure or any function of the body of man or other animals . . . .” 103
Thus, surgeries, for example, are not drugs. Practitioners and
researchers describe AARTs as “research protocol[s],” and not drugs,
when explaining why AARTs are outside of the jurisdiction of the
FDA. 104 Because the definition of drug includes the word “article” and
not “research protocol,” AARTs are analogous to surgeries and not
drugs. Similarly, methods used in assisted reproduction such as in vitro
fertilization and artificial insemination are not subject to FDA
approval. 105 Thus, because AARTs are techniques that use drugs and
medical devices, just like other forms of assisted reproductive
technology, AARTs should not be subject to federal regulation. 106
Additionally, while other scholarly articles have noted that cytoplasmic
transfer could be seen as a “cure” for the disease of infertility, women
who would use mitochondrial transfer are not infertile. 107
101 See discussion infra Section II.D (providing information on the FDA’s Human Cellular
and Tissue-Based Products Rule in the context of sexually intimate partners). For more on the
procurement and trade of sperm and eggs, see generally CAHN, supra note 1.
102 21 U.S.C. § 355; see also MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at
64–65 (discussing the Food, Drug, and Cosmetic Act and the process through which a proposed
drug eventually gains FDA approval for sale in the United States: If an investigational new drug
application is authorized, then a researcher may begin clinical investigations. After successful
clinical investigations, a researcher (or company) may submit “a Biologic License
Application . . . or a New Drug Application . . . .” That application is then reviewed by the FDA
which decides whether to approve the drug.).
103 21 U.S.C. §§ 321(g)(1)(B)–(C).
104 Meeting #32 Transcript, supra note 8, at 280–81.
105 See What Is Assisted Reproductive Technology?, CENTERS DISEASE CONTROL &
PREVENTION, http://www.cdc.gov/art/whatis.html (last updated Feb. 7, 2017).
106 See Michael J. Malinowski, A Law-Policy Proposal to Know Where Babies Come from
During the Reproduction Revolution, 9 J. GENDER RACE & JUST. 549, 554–55 (2006).
107 See Kerry L. Macintosh, Brave New Eugenics: Regulating Assisted Reproductive
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 259 (2010).
Thus, to the extent that other forms of assisted reproductive technology could arguably be
considered a “cure” for infertility, thus rendering them analogous to a drug, mitochondrial
transfer does not cure a mother’s infertility as she would be able to reproduce without the use
of assisted reproductive technology. See supra text accompanying note 103 (providing the
definition of a drug).
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“Biological products,” also referred to as “biologics” are a broad
category of products regulated by the FDA. 108 A biological product is “a
virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood
component or derivative, allergenic product, protein . . . or analogous
product, . . . arsphenamine or derivative of arsphenamine, . . . applicable
to the prevention, treatment, or cure of a disease or condition of human
beings.” 109 So while organ transplants are not regulated by the FDA,
“[b]lood and processed blood derivatives, such as plasma and clotting
factors,” are regulated by the FDA under the Public Health Service
Act. 110
The FDA has stated that advanced assisted reproductive
technologies would be regulated “as drugs and/or biological products,”
but it is unclear why that is the case. 111 Similarly, the FDA has used this
tactic in spite of the legal argument that cytoplasmic transfer and
mitochondrial transfer are not drugs, but medical techniques which do
not fall under the Agency’s jurisdiction. 112 The FDA should clearly
explain the source of its jurisdiction (if any) over advanced assisted
reproductive technologies and how that jurisdiction corresponds with
the manner in which advanced assisted reproductive technologies will
be regulated. In light of the blurring distinctions between medical
devices, human tissues, drugs, and the practice of medicine, if the FDA
does have jurisdiction over advanced assisted reproductive technologies,
it should clearly explain the source of that jurisdiction, not only to
regulate more clearly, but also because the Agency’s jurisdiction over
biotechnology will continue to be contested as scientists continue to
innovate and move from using pharmaceuticals to treat conditions, to
using them to prevent conditions ex ante while employing techniques
that target genes.
D.

The Gradual Inclusion of Reproductive Tissue into FDA

See 42 U.S.C. § 262 (2012).
Id.
110 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 1154 (4th ed.
2014) (noting that “[a] relatively small share of blood is used in the form in which it was
collected, i.e., as single units transfused into individual patients. Here the risk of disease
transmission is confined; only the recipient of a contaminated unit of blood is potentially
vulnerable. But most blood is fractionated, pooled, and processed to yield a variety of useful
products”). For statutory provisions governing organ transplantation, see 42 U.S.C. §§ 273–74.
111 FDA Regulation of Human Cells, supra note 12; see also HUTT ET AL., supra note 110, at
672. This dual designation may stem from the FDA’s efforts to regulate products that fall within
both categories of its regulations; however, the agency has not even issued a clarification as to
which FDA regulatory center would review applications by those wishing to use advanced
assisted reproductive technologies clinically. Furthermore, there has still been no clear
explanation as to how an advanced assisted reproductive technology would be a drug or a
biologic.
112 See Meeting #32 Transcript, supra note 8, at 280.
108
109
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Regulations
Over time, the FDA has increased the number of agency-issued
rules that apply to human reproductive tissue and advanced assisted
reproductive technologies. The FDA’s July 6, 2001 letter to
sponsors/researchers referenced five documents that the FDA
characterized as providing “notice of the applicability of [investigational
new drug] requirements to cellular and tissue-based products . . . .”113
These five documents were: two guidance documents, one final rule,
and two proposed rules. 114 However, a close examination of these five
documents reveals that notice is non-existent in some of those
documents and unclear in the others.
Assisted reproductive technology, which includes not only in vitro
fertilization but also artificial insemination, had been used by American
physicians for over fifty years before the FDA began regulating
reproductive tissue. 115 In 1993, the FDA issued a document entitled,
“Application of Current Statutory Authorities to Human Somatic Cell
Therapy Products and Gene Therapy Products.” 116 This document,
while cited in the July 6, 2001 FDA letter, did not state that the FDA
would be regulating advanced assisted reproductive technologies or

See infra Appendix A.
Id. The five documents were: (1) a 1993 Federal Register notice entitled, “Application of
Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy
Products,” 58 Fed. Reg. 53,248 (Oct. 14, 1993); (2) the FDA’s “comprehensive regulatory
program for the regulation of human cellular and tissue-based products, based on a tiered, riskbased assessment,” infra Appendix A; see Proposed Approach to Regulation of Cellular and
Tissue-Based Products; Availability and Public Meeting, 62 Fed. Reg. 9721 (Mar. 4, 1997); (3)
“[a] final rule that establishes the criteria for regulation of human cells, tissues, and cellular and
tissue based products (HCT/Ps), including reproductive cells and tissues,” infra Appendix A;
see Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration
and Listing, 66 Fed. Reg. 5447 (Jan. 19, 2001); (4) a 1999 proposed rule entitled, “Suitability
Determination for Donors of Human Cellular and Tissue-Based Products,” 64 Fed. Reg. 52,696
(proposed Sept. 30, 1999); and (5) a 2001 proposed rule entitled, “Current Good Tissue Practice
for Manufacturers of Human Cellular and Tissue-Based Products; Inspection and
Enforcement,” 66 Fed. Reg. 1508 (proposed Jan. 8, 2001).
115 It is estimated that the “popular use” of artificial insemination in the United States began
in the 1940s. See NAT’L BIOETHICS ADVISORY COMM’N, CLONING HUMAN BEINGS 5 (1997)
[hereinafter CLONING HUMAN BEINGS] (“Artificial insemination by donor, for example, was
considered a form of adultery when first introduced in the 1940s. It is now a widely used and
accepted practice in the treatment of infertility, although some continue to have serious
reservations.”); Gaia Bernstein, The Socio-Legal Acceptance of New Technologies: A Close Look
at Artificial Insemination, 77 WASH. L. REV. 1035, 1060–72 (2002); see also The US’ First Test
Tube Baby, PBS, http://ec2-184-73-243-168.compute-1.amazonaws.com/wgbh/american
experience/features/general-article/babies-americas-first (last visited Mar. 1, 2018) (noting that
Elizabeth Carr, the first baby born as a result of in vitro fertilization in the United States, was
born in 1981).
116 See Application of Current Statutory Authorities to Human Somatic Cell Therapy
Products and Gene Therapy Products, 58 Fed. Reg. 53,248.
113
114
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mention reproductive tissue at all. 117

Figure 1: Timeline of the Increasing Federal Regulation of
AARTs 118

In 1997, when the FDA issued a “Proposed Approach to the
Regulation of Cellular and Tissue-Based Products,” the FDA noted that
the Agency “ha[d] not previously regulated reproductive tissues.” 119 The
Federal Register notice for the 1997 Proposed Approach stated that the
FDA’s regulatory framework would include reproductive tissues.120
However, the actual document providing the approach stated that the
FDA “would recommend, but not require, that screening and testing
procedures be followed when reproductive tissues are used between
sexually intimate partners . . . .” 121 Thus, the FDA’s regulation of
reproductive tissue began with confusion. Ultimately, the 1997 “Human
Id.
The dates in this timeline are a compilation of several sources cited in this Article. See
supra note 115 and accompanying text (regarding artificial insemination); see also 42 U.S.C.
§ 264 (2012); Meeting #32 Transcript, supra note 8, at 280–81; US’ First Test Tube Baby, supra
note 115 (referring to the birth of Elizabeth Carr in 1981); supra note 49 (describing the 1992
Fertility Clinic Success Rate and Certification Act). For more on the gradual increase of federal
regulations applicable to assisted reproductive technology and AARTs, see infra text
accompanying notes 119–23 (regarding the 1997 document, a “Proposed Approach to
Regulation of Cellular and Tissue-Based Products” and the 1999 document “Suitability
Determination for Donors of Human Cellular and Tissue-Based Products”).
119 FOOD & DRUG ADMIN., PROPOSED APPROACH TO REGULATION OF CELLULAR AND
TISSUE-BASED PRODUCTS 9 (1997) [hereinafter FDA PROPOSED APPROACH].
120 See Proposed Approach to Regulation of Cellular and Tissue-Based Products; Availability
and Public Meeting, 62 Fed. Reg. 9721 (Mar. 4, 1997).
121 FDA PROPOSED APPROACH, supra note 119.
117
118
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Tissue Intended for Transplantation” rule specifically excluded “semen
or other reproductive tissue.” 122
In 1999, the FDA flipped from not regulating reproductive tissue to
proposing a rule that would require the application of communicable
disease testing requirements to facilities that work with reproductive
tissue. The proposed “Suitability Determination for Donors of Human
Cellular and Tissue-Based Products” rule would mandate
communicable disease testing for many types of human tissue including
semen. 123 The FDA explained that because human cell, tissue, and
cellular and tissue-based products (which the agency refers to as
“HCT/Ps”) are derived from the human body, there is a risk that these
“products” could transmit communicable diseases. 124 As the basis for its
HCT/P regulations, the FDA cited to Section 361 of the Public Health
Service Act which allows the FDA, by delegation, to make regulations to
prohibit the transmission or spread of communicable diseases. 125 As a
result, under the final rule, facilities that perform work on reproductive
tissues must continue to adhere to requirements related to the testing of
communicable diseases with exceptions for those facilities that are using
the reproductive tissue of sexually intimate partners. 126
122

1997).

See Human Tissue Intended for Transplantation, 62 Fed. Reg. 40,429, 40,444 (July 29,

123 See Statement of Kathryn C. Zoon, supra note 72. The 1999 Suitability Determination for
Donors of Human Cellular and Tissue-Based Products proposed rule cited in the July 6, 2001
letter became a final rule in 2004. However, in response to a public comment, the name of the
final rule was changed to “Eligibility Determination for Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products,” 69 Fed. Reg. 29,786 (May 25, 2005). The final rule covers
many types of human tissue: reproductive tissue including embryos, semen, and eggs; cord
blood; ocular tissue such as cornea donations through eye banks; and human “heart valves.” Id.
at 29,817, 29,787 (“We are issuing these new regulations under the authority of section 361 of
the [Public Health Service] Act (42 U.S.C. 264).”).
124 See Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and
Tissue-Based Products, 69 Fed. Reg. at 29,787; Donor Eligibility Final Rule and Guidance
Questions and Answers, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/BiologicsBlood
Vaccines/TissueTissueProducts/QuestionsaboutTissues/ucm102842.htm (last updated Apr. 20,
2009) (citing to Section 351 of the Public Health Service Act in reference to a biological product
application).
125 See 42 U.S.C. § 264 (2012); Donor Eligibility Final Rule and Guidance Questions and
Answers, supra note 124; see also Eligibility Determination for Donors of Human Cells, Tissues,
and Cellular and Tissue-Based Products, 69 Fed. Reg. at 29,788.
126 See Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and
Tissue-Based Products, 69 Fed. Reg. at 29,793 (“We have also clarified the definition by noting
that directed reproductive donors do not include sexually intimate donors, who are excepted
from screening and testing requirements under § 1271.90.”) Anonymous semen donations
remain subject to the testing requirement and six-month retesting requirement. The FDA
attributes the distinction in the regulatory treatment of anonymous semen donors and sexually
intimate partners to the Agency’s “respect [of] the existence of relationships between people
who know each other and have made a joint decision for the recipient to conceive a child.” Id.
at 29,790, 29,793 (noting that facilities working with the reproductive tissue of sexually intimate
partners are not excepted from administrative requirements such as labeling and registration
when semen from a directed donor is frozen before insemination due to “concerns about
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The FDA’s 2001 HCT/P regulations are the basis for the FDA’s
theory that the results of advanced assisted reproductive technologies
are “drugs.”127 The FDA’s tissue regulation framework conceptually
distinguishes between “minimally manipulated” tissue and “more than
minimally manipulated” tissue. 128 “Minimal manipulation” is:
“processing that does not alter the original relevant characteristics of the
tissue relating to the tissue’s utility for reconstruction, repair, or
replacement . . . [or] the relevant biological characteristics of cells or
tissues.” 129
The regulations do not define what the term “original relevant
characteristics” means and despite public comments that the term
“minimal manipulation” is vague and should be eliminated, the FDA
kept the term. 130 Tissues that are minimally manipulated are “lightly
regulated” and subject to communicable disease testing requirements,
whereas “more than minimally” manipulated human cells and tissue
products are regulated as drugs and/or biologics. 131 Not only is it
possible cross-contamination during storage”). The fifth document referenced in the July 6,
2001 letter infra Appendix A, “Current Good Tissue Practice for Manufacturers of Human
Cellular and Tissue-Based Products; Inspection and Enforcement,” also provides requirements
to minimize the transmission of communicable diseases within facilities. 66 Fed. Reg. 1508
(Jan. 8, 2001). The final rule, “Current Good Tissue Practice for Human Cell, Tissue, and
Cellular and Tissue-Based Product Establishments; Inspection and Enforcement” was published
on November 24, 2004 with an effective date of May 25, 2005. 69 Fed. Reg. 68,611 (Nov. 24,
2004).
127 See Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment
Registration and Listing, 66 Fed. Reg. 5447 (Jan. 19, 2001); Tissue and Tissue Product Questions
and Answers, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/BiologicsBloodVaccines/Tissue
TissueProducts/QuestionsaboutTissues/ucm101559.htm (last updated Feb. 2, 2018);
MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 22; see also 21 C.F.R.
§ 1271.3(d) (2016). Blood, blood products, and blood vessels are excluded from the agency’s
HCT/P regulations. The 2001 Human Tissue Regulations do not apply to human organs such as
kidneys, livers, hearts, and lungs as they are regulated by the Health Resources Services
Administration, another operating division of the U.S. Department of Health and Human
Services. Id.
128 See Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment
Registration and Listing, 66 Fed. Reg. at 5457.
129 Id. at 5467.
130 Id. at 5457 (“Eight comments asserted that ‘minimal manipulation’ is vague and open to
subjective interpretation, and should be eliminated. Two comments asserted that it is difficult
to draw a meaningful distinction between tissues that are minimally manipulated and those that
are more than minimally manipulated. One of these comments suggested that instead of the
minimal manipulation criterion, FDA should propose that tissue products labeled or promoted
for tissue replacement, reconstruction, or restoration of function be regulated as tissue.
Another comment requested the development of guidance and noted that, in light of future
technological advances, a broader definition of minimal manipulation may be more
appropriate.”).
131 See Collins, supra note 49 (showing the impact of the FDA’s regulatory scheme on federal
funding and the acceptance of the FDA’s view by other agencies within the U.S. Department of
Health and Human Services: “The Public Health Service Act and the Federal Food, Drug, and
Cosmetic Act give the FDA the authority to regulate cell and gene therapy products as
biological products and/or drugs, which would include oversight of human germline
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unclear what more than minimal manipulation is, it is also unclear how
the FDA’s ability to require communicable disease screening under the
Public Health Service Act mandates that a “modified embryo” or more
than minimally manipulated reproductive tissue be treated as a “drug
and/or biologic.” 132
The FDA’s HCT/P regulations are based on the Agency’s delegated
communicable disease testing authority under the Public Health Service
Act; however, it is unclear how communicable disease testing
requirements can prohibit the clinical use of AARTs. 133 While
communicable disease testing for public health purposes is an
undisputed part of the U.S. Department of Health and Human Services’
modification. During development, biological products may be used in humans only if an
investigational new drug application is in effect (21 CFR Part 312).”); see also U.S. DEP’T.
HEALTH & HUMAN SERVS., U.S. FOOD & DRUG ADMIN., MINIMAL MANIPULATION OF HUMAN
CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE (2014),
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory
Information/Guidances/CellularandGeneTherapy/UCM427746.pdf;
MITOCHONDRIAL
REPLACEMENT TECHNIQUES, supra note 29, at 2–27.
132 See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 65. In 2013, the FDA
sent a letter to OvaScience, a Massachusetts-based company, stating that the company needed
to submit an investigational new drug application to continue its work on “Augment,” a
technology that uses a woman’s own mitochondria to revitalize her eggs which are then used in
in vitro fertilization. This letter, obtained through FOIA Request 2016-4882, stated, on the
subject of “more than minimal manipulation”:
[O]ur understanding is that your autologous mitochondrial transfer product,
AUGMENT, consists of cells isolated from a biopsy of ovarian tissue, which are
processed to extract mitochondria that are then introduced into other reproductive
tissues during the IVF process. The removal of mitochondria and introduction into
other reproductive tissue appears to be more than minimal manipulation. This is
based on the limited information available; please note that the addition of
mitochondrial DNA to other reproductive tissue may raise additional regulatory
concerns.
Letter from Celia M. Witten to Alison Lawton, supra note 7; see Complaint at 2, Ratner v.
OvaScience, No. 13-cv-12286 (D. Mass. Sept. 16, 2013) (“Throughout the Class Period,
Ova[S]cience represented to the FDA and investors that it believed that Augment qualified for
designation as a 361 HCT/P, which allows human cellular and tissue based products to be
tested and marketed without FDA licensure. Under FDA guidelines, organisms can only
achieve this designation if they are ‘only minimally manipulated’, i.e., the process does not alter
‘the relevant biological characteristics of the cells or tissue.’ . . . Ultimately, the FDA rejected
Ova[S]cience’s faulty designation. On September 10, 2013, the Company disclosed that it was
suspending enrollment of AUGMENT in the U.S. after receiving an ‘untitled’ letter from the
FDA ‘questioning the status of AUGMENT as a 361 HCT/P and advising the Company to file
an Investigational New Drug (IND) application.’”); see also Bioentrepreneur, CRISPR Germline
Editing Reverberates Through Biotech Community, NATURE.COM: TRADESECRETS (Apr. 30,
2015, 12:34 AM), http://blogs.nature.com/tradesecrets/2015/04/30/crispr-germline-editingreverberates-through-biotech-community (noting that Augment is available in the United
Kingdom, Canada, Dubai, and Turkey, but not in the United States); HUTT ET AL., supra note
110, at 672.
133 See 42 U.S.C. § 264 (2012); Eligibility Determination for Donors of Human Cells, Tissues,
and Cellular and Tissue-Based Products; Final Rule and Notice, 69 Fed. Reg. 29,786, 29,787
(May 25, 2004); Donor Eligibility Final Rule and Guidance Questions and Answers, supra note
124.
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jurisdiction (and by delegation, the FDA’s), the FDA’s regulation of
reproductive tissues has expanded beyond communicable disease testing
requirements. 134 Regulating manipulated cells and tissues utilized in
advanced assisted reproductive technology as drugs exceeds the power
to regulate communicable diseases. Neither interstate commerce nor
international commerce would affect the transmission or spread of
defective mitochondria or defective genes. If genetic diseases did
somehow fall within the Agency’s authority to prevent the spread of
communicable diseases under the Public Health Service Act, the
Agency’s letters have thwarted efforts to prevent the transmission of
disease-causing genetic mutations to offspring.
In none of the five documents cited by the FDA in its July 6, 2001
letter did the FDA clearly explain how these documents connected to
the Agency’s enabling statutes and how the Agency’s statutory authority
enabled it to prevent the use of technology that modified DNA in
reproduction. Some of the cited documents stated that the FDA did not
regulate reproductive tissue, whereas others provided regulations
related to reproductive tissue. Others were “guidance documents,”
which do not provide legal requirements. 135 In those documents that did
provide legal requirements, the Agency broadly cited to Section 361 of
the Public Health Service Act and the Federal Food, Drug, and Cosmetic
Act generally. Yet, the authority to inhibit the spread of communicable
disease is not the same as the authority to regulate genetic
modifications. Moreover, the applicability of the Federal Food, Drug,
and Cosmetic Act, if any, was not explained.
Not only is the regulatory framework surrounding advanced
assisted reproductive technologies unclear, but the manner of regulating
these technologies is unique as compared to other more traditional
forms of assisted reproductive technology. To the FDA, advanced
assisted reproductive technologies differ from “more traditional”
methods of assisted reproductive technology because they involve the
use of more than minimally manipulated tissue. 136 But why does a
See 42 U.S.C. § 264; FDA PROPOSED APPROACH, supra note 119, at 8–9; see also HUTT ET
supra note 110, at 77 (explaining that the FDA shares the power to prevent the spread of
communicable diseases with the Centers for Disease Control and Prevention).
135 See Todd D. Rakoff, The Choice Between Formal and Informal Modes of Administrative
Regulation, 52 ADMIN. L. REV. 159, 168 (2000) (“At the same time, the FDA takes pains to state
that guidance documents ‘are not legally binding on the public or the agency. Rather, they
explain how the agency believes the statutes and regulations apply to certain regulated
activities.’ Indeed, the FDA remains open to discussing ‘[a]lternative methods that comply with
the [applicable] statute or regulations . . . .’ In short, guidance documents are meant to be
statements of no legal consequence but immense practical consequence about virtually
everything the agency regulates.” (quoting The Food and Drug Administration’s Development,
Issuance, and Use of Guidance Documents, 62 Fed. Reg. 8961, 8967 (Feb. 27, 1997))).
136 “Traditional” assisted reproductive technology, meaning assisted reproductive
technology such as in vitro fertilization not involving genetic modifications or artificial
insemination, remain “minimally regulated” by the FDA, whereas AARTs are heavily regulated.
134

AL.,

2018]

SUBTERRANEAN REGULATION

1271

change of 0.054% of total DNA, such as occurs in mitochondrial
transfer, result in a classification of more than minimal manipulation?
The FDA has not answered this question and declined requests to use a
term that was not “vague” and “misleading” such as “more than
minimal manipulation.” 137 In light of the fact that only 0.054% of an
embryo’s DNA is modified as a result of mitochondrial transfer, it
appears that at the very least, the term “minimal manipulation” should
be replaced with “manipulation.”
There are additional questions related to the regulatory treatment
of human reproductive tissue as a “drug” or “biologic.” If a “modified
embryo” is a drug, does that mean that a child born as a result of an
advanced assisted reproductive technology is a “drug”? How long are
future humans “drugs” or at what point do modified embryos become
humans and not drugs? 138 At some point, in theory, a child born as a
result of advanced assisted reproductive technology must pass from
being a “drug” into being a nonregulated entity, but it is unclear when
that occurs.
III. THE ETHICAL CONCERNS THAT SILENTLY IMPACT THE FDA’S
REGULATORY ACTIONS RELATED TO ADVANCED ASSISTED REPRODUCTIVE
TECHNOLOGIES
When the FDA regulates advanced assisted reproductive
technologies in a subterranean manner, ethical concerns can fuse with
safety concerns. 139 In written communications, the FDA has not
See supra note 1 and accompanying text (regarding the regulation of traditional assisted
reproductive technology); supra text accompanying note 129 (providing the definition of
“minimal manipulation”).
137 See supra note 130 and accompanying text (providing public comments on the FDA’s
HCT/P regulations).
138 See 21 U.S.C. § 321(g)(1) (2012) (defining “drugs” as “articles intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals;
and . . . articles (other than food) intended to affect the structure or any function of the body of
man or other animals”). But see LA. STAT. ANN. § 9:129 (2017) (“A viable in vitro fertilized
human ovum is a juridical person which shall not be intentionally destroyed by any natural or
other juridical person or through the actions of any other such person. An in vitro fertilized
human ovum that fails to develop further over a thirty-six hour period except when the embryo
is in a state of cryopreservation, is considered non-viable and is not considered a juridical
person.”). See Letter from Mary A. Malarkey, Dir., Office of Compliance & Biologics Quality,
U.S. Food & Drug Admin., to John Zhang, Chief Exec. Officer, Darwin Life, Inc. & New Hope
Fertility Ctr. (Aug. 4, 2017), https://www.fda.gov/downloads/BiologicsBloodVaccines/Guidance
ComplianceRegulatoryInformation/ComplianceActivities/Enforcement/UntitledLetters/
UCM570225.pdf (referring to “genetically modified embryo[s]”).
139 See Connor, supra note 12 (Dr. Grifo stated with “it”—in the subsequent statement—
referring to pronuclear transfer, a type of mitochondrial transfer: “I stopped it because the FDA
stopped me for safety concerns. Initially they said it was because it was cloning, which they
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indicated that the science surrounding advanced assisted reproductive
technologies is misunderstood. 140 Yet some statements by FDA officials
in public settings indicate that safety or scientific comprehension are
not driving the FDA’s decisions related to AARTs; if that is indeed the
case, then other considerations must be driving the FDA’s subterranean
actions. I argue that these “other considerations” that drive the FDA’s
subterranean regulation of AARTs include ethical concerns and political
opposition to advanced assisted reproductive technologies.
While FDA employees acknowledge that ethical concerns can
affect regulatory actions, the Agency generally avoids discussing or
identifying those ethical concerns. At the 2014 FDA Cellular, Tissue,
and Gene Therapies Advisory Committee meeting, an FDA employee
stated that “[t]he FDA recognizes [that there are] moral, ethical, and
social policy issues related to genetic modification of eggs and embryos,
and that these issues have the potential to affect regulatory decisions.” 141
But in spite of their ability to affect regulatory decisions, the Agency
continually refuses to discuss these issues. In 2014—at the same
Advisory Committee meeting on mitochondrial transfer where an
agency employee admitted that ethical concerns can influence agency
actions—the Agency purposefully limited the scope of the meeting to
animal trials and general safety concerns, but not the legal and ethical
issues surrounding the technique. 142 One FDA employee announced at
the 2014 Advisory Committee meeting that the “FDA is [cognizant] that
there are ethical, legal, and social policy issues raised by such heritable
didn’t understand that it wasn’t. Then they said they had to regulate it on the basis that it was
genetic engineering”); Human Cloning: How Close Is It?, supra note 71; see also Meeting #32
Transcript, supra note 8, at 46 (“In March of 2001, a laboratory of Dr. Jacques Cohen reported
that two children born after the ooplasm transfer protocol were heteroplasmic, which means
the genotypes of both the ooplasm donor and the mother could be detected in their tissues.
These children were approximately one year old at the time of this analysis, so this was a
persistent heteroplasmy that had been maintained. At the time of Dr. Cohen’s publication the
FDA was already considering action in the area of ooplasm transfer. The report of
heteroplasmy raised . . . concerns, as did information [that] two pregnancies occurring after
ooplasm transfer resulted in fetuses with Turner’s syndrome, a condition where there is only
one X chromosome.”); PREVENTING MITOCHONDRIAL DISEASE, supra note 12.
140 See Meeting #59 Transcript, supra note 32. In the FDA-prepared briefing document, the
Agency explained the science underlying both mitochondrial transfer and cytoplasmic transfer.
The Agency’s briefing document also described “some of the key safety issues that have been
identified” in the study of mitochondrial transfer. None of these identified “safety” issues
overlapped with ethical issues. Id. Also, the term “safety” has various definitions as many of the
agency’s regulated products, namely pharmaceuticals, result in serious side effects. See Meeting
#32 Transcript, supra note 8, at 47 (“FDA had concerns about whether we understood all the
ramifications of this procedure and whether we understood its safety in particular, and reacted
by sending letters to practitioners who were identified by publications on ooplasm [cytoplasm]
transfer or by advertisements offering the procedure. We advised practitioners that we would
now require the submission of an investigational new drug application, or IND, to the agency
and its subsequent review to continue to treat new patients.”).
141 Meeting #59 Transcript, supra note 32, at 13 (emphasis added).
142 See id. at 11–13, 25.
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genetic modification of gametes, but these [a]re outside of FDA’s
delegated authority, and will not be discussed at this meeting.”143 The
Agency did not hold a subsequent meeting to address the remaining
legal and ethical issues.
Legal issues were similarly avoided during a 2002 Advisory
Committee meeting after the issuance of Untitled Letters to researchers
on cytoplasmic transfer. 144 There, an FDA employee informed attendees
of the meeting that it would “limit . . . discussion to the science behind
[cytoplasmic] transfer and not extend that discussion to FDA’s
jurisdiction in general, FDA’s proposed rules for the regulation of
human cells and tissues and other assisted reproductive technologies.”145
Thus, in spite of the importance of legal interpretation in the regulation
of advanced assisted reproductive technologies, the Agency has avoided
discussions of its jurisdiction and its position on ethical issues.
The public statements of FDA officials, as evidenced by the
testimony of agency officials before Congress from 1997 to 2016 and
FDA employees’ statements in other venues between 2000 and 2016
allude to the ethical concerns that may underlie the FDA’s regulatory
decision-making process. 146 When subterranean regulatory actions
occur, it is possible, for example, that Agency officials are not acting
based on the political beliefs of the President or sound legal
interpretation, but instead institutional or individual views on ethics.
Transparent regulation would help to prevent this by clarifying what (or
whose) ethical perspectives are being incorporated into regulatory
decisions and the source of those ethical perspectives.
In spite of the unidentified basis for its assertion of jurisdiction, Dr.
Kathryn Zoon, an FDA official, still asserted in congressional testimony
that an investigational new drug application had to be submitted by a
researcher before the commencement of “[c]linical research using
cloning technology to clone a human being,” although the agency would
Id. at 17–18.
See Meeting #32 Transcript, supra note 8, at 47.
145 Id. at 48.
146 See Congressional Testimony 2017, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/News
Events/Testimony/ucm383860.htm (last updated June 22, 2016) (containing FDA testimony
from 1997 to 2016); Speeches by FDA Officials, U.S. FOOD & DRUG ADMIN., https://
www.fda.gov/NewsEvents/Speeches/default.htm (last updated Oct. 18, 2016). Note, while the
FDA posts the speeches of “agency officials” on the websites, this does not mean that the
speeches of all agency employees are posted online. For example, the speech by FDA
Commissioner Robert M. Califf to the 2016 Food Drug and Law Institute Annual Meeting is
available online; however, the subsequent speech by the Agency’s Chief Counsel, Elizabeth
Dickinson, is not maintained in the speeches repository. See Robert M. Califf, Comm’r, Speech
at 2016 FDLI Annual Meeting (May 5, 2016), https://wayback.archive-it.org/7993/
20170111003315/http://www.fda.gov/NewsEvents/Speeches/ucm499475.htm (“The good news
is that after I’m done you’ll hear from FDA’s top lawyer, Liz Dickinson.”). The speeches
archived on the FDA website span from 1988 until 2016; however, there are very few from 1988
to 2005.
143
144
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not permit any such clinical investigation to proceed due to “major
unresolved safety questions . . . .” 147 These unresolved safety questions
were not identified. Yet, a statement later in Dr. Zoon’s testimony
explained that safety issues were not the only reason for the Agency’s
opposition to cloning: “Because of the profound moral, ethical, and
scientific issues, the Administration is unequivocally opposed to the
cloning of human beings.” 148 Dr. Zoon’s reference to “the
Administration” was likely her referring to the Food and Drug
Administration; however, the Food and Drug Administration is a part
of the executive branch and not an independent regulatory agency, so it
is possible that political concerns affected her testimony. 149 These same
concerns have surfaced in relation to other advanced assisted
reproductive technologies and assisted reproductive technology in
general, which forces politicians to consider their positions on
reproductive rights. Much has been written in the administrative
literature about the political pressures that administrative agencies face;
here, ethical issues such as those related to the destruction of embryos,
eugenics, and concerns about modifications of genetic material for
future generations, have possibly commingled with political concerns
and pressures. 150 Thus, while Chevron deference and issues of
“reasonable” agency interpretation of a statute arise within this
discussion of the FDA’s regulation of AARTs, it needs to be clear what
aspect of the FDA’s decision is based on statutory interpretation (and of
course, what statute is being interpreted), and what aspect of that
interpretation is based on ethics—which would be entitled to less
deference. 151
A.

Embryo Destruction and Research: Current Iterations of a
Decades-Long Debate

The destruction of embryos and controversy related to research on
embryonic tissue are likely additional “moral, ethical, and social policy
Statement of Kathryn C. Zoon, supra note 72.
Id.
149 See FDA Laws, Regulations, and Guidance Documents, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/downloads/BiologicsBloodVaccines/InternationalActivities/
UCM273183.pdf (last visited June 13, 2016). For more on the differences between independent
regulatory agencies and federal agencies that are a part of the Executive Branch, see Kirti Datla
& Richard L. Revesz, Deconstructing Independent Agencies (and Executive Agencies), 98
CORNELL L. REV. 769, 776 n.24 (2013).
150 For a general overview of pressures faced by administrative agencies, see Seidenfeld,
supra note 82.
151 For more on Chevron deference, see Peter L. Strauss, “Deference” Is Too Confusing—Let’s
Call Them “Chevron Space” and “Skidmore Weight”, 112 COLUM. L. REV. 1143 (2012).
147
148
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issues related to genetic modification of eggs and embryos . . . [with the]
potential to affect regulatory decisions.” 152 In addition to research on
embryos, another issue that arises in discussions of the ethics of
mitochondrial transfer is the destruction of embryos. 153 The Institute of
Medicine, in a report commissioned by the FDA, also recognized the
“moral status of the embryo” as an ethical issue related to mitochondrial
transfer. 154 This report identified this issue, but did not analyze it nor
explain how the FDA had incorporated that “moral issue” into its
regulatory decision-making before. 155
Ethical concerns have impacted federal funding decisions related to
embryonic research for years. 156 However, the idea that ethical concerns
could manifest as legal prohibitions on access to reproductive
technology regardless of funding sources, has not received as much
attention outside of discussions about access to abortion and
contraception. 157
There are many ethical issues that are ripe for a public discussion.
Questions about where one “draws the line” between ethical and
unethical medical practices have accompanied assisted reproductive
technology since its inception. 158 Mitochondrial transfer, beyond issues
152 Meeting #59 Transcript, supra note 32, at 13; see also James Gallagher, Three-Person
Babies - Not Three-Parent Babies, BBC (Feb. 1, 2015), http://www.bbc.com/news/health31044255; MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 7–9.
153 See Gallagher, supra note 152; MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note
29, at 5–11.
154 MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 102–06. The Institute of
Medicine recommended that non-viable human embryos be used “when possible” in preclinical
research related to mitochondrial transfer. Id. at 12.
155 Id. at 1–2. After the 2014 Advisory Committee meetings on February 25-26, 2014, the
FDA’s Center for Biologics Evaluation and Research, Office of Cellular, Tissue, and Gene
Therapies requested that a committee of the Institute of Medicine “develop a report that
[would] inform the [FDA] in consideration of review of applications in the area of genetic
modification of eggs and zygotes for the prevention of mitochondrial disease specific to
mitochondrial DNA . . . including maternal spindle transfer, pronuclear transfer, . . . polar body
transfer . . . and [possibly] other technologies not currently proposed.” Id. at 2.
156 See Carbone, supra note 91, at 348 (“The ban on use of federal funds for embryo
experimentation makes it difficult to undertake the expensive testing that might persuade the
FDA to authorize use of the technique; that testing today is taking place in Britain, not the U.S.”
(citations omitted)). For more on funding policies affecting embryo research, see O. Carter
Snead, Science, Public Bioethics, and the Problem of Integration, 43 U.C. DAVIS L. REV. 1529,
1552–53 (2010).
157 See HUTT ET AL., supra note 110, at 18 (“Recently, however, both the George W. Bush
Administration and the Obama administration have generated controversy by interfering in the
FDA decision making process regarding petitions to institute and expand over-the-counter
availability of Plan B emergency contraceptives.”). “No Rx/OTC switch in history has attracted
more attention than the switch of the emergency contraceptive, Plan B, from prescription to
nonprescription status.” Id. at 966.
158 See CLONING HUMAN BEINGS, supra note 115, at 5 (“Artificial insemination by donor, for
example, was considered a form of adultery when first introduced in the 1940s. . . . When
prenatal diagnosis was introduced in the late 1960s, the public simultaneously welcomed the
opportunity to prevent lethal disease in newborns but worried about the use of such techniques
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of embryo storage and disposition, inevitably involves the destruction of
reproductive tissue. 159 Yet, part of the difference between these longstanding issues resultant from the use of conventional assisted
reproductive technology and the ethical issues resultant from the use of
advanced assisted reproductive technologies is that the implicit
resolution of the ethical issues related to the use of AARTs differs from
the regulatory treatment of the ethical issues presented by the use of
conventional assisted reproductive technology: by not asserting any
interest in regulating conventional forms of assisted reproduction or
diagnostic techniques such as pre-implantation genetic diagnosis or in
vitro fertilization, which are other techniques that can also contribute to
the destruction of embryos, the FDA essentially left these ethical
questions to individual states. Now, by comparison, however, the FDA
is at least partially making a decision on ethics as it relates to advanced
assisted reproductive technologies and targeting them for oversight,
which is a change from the Agency’s previous regulatory position.
B.

Germline Modification: Changing the “Shared” Human
Identity

Germline modification is an ethical issue not only for advanced
assisted reproductive technologies, but also for genome editing through
CRISPR-Cas9 and other technologies that permit genome editing.160
Part of the discussion of this ethical issue centers on what even
constitutes the “germline” or a “germline modification.” 161 There is no
uniform definition of the human germline. 162 “In place of [the term]
germline, some prefer the term ‘inheritable genetic modification.’” 163
Nonetheless, some of the ethical objection to modifying the germline
comes from arguments related to kinship and the belief that a shared
human germline unites humankind. 164
to select ‘vanity’ characteristics or nonmedical traits in offspring. The birth of Louise Brown,
conceived via in vitro fertilization, in 1978 was another dramatic event, providing a new and
controversial means to parenthood.”).
159 See Ian Sample, “Three-Parent” Babies Explained: What Are the Concerns and Are They
Justified?, GUARDIAN (Feb. 2, 2015, 10:56 AM), https://www.theguardian.com/science/2015/feb/
02/three-parent-babies-explained; see also Paula Amato et al., Three-Parent In Vitro
Fertilization: Gene Replacement for the Prevention of Inherited Mitochondrial Diseases, 101
FERTILITY & STERILITY 31 (2014).
160 See Callaway, supra note 23; see also Regalado, supra note 23.
161 See FRANKEL & HAGEN, supra note 31, at 4–6; discussion supra Part I.
162 See FRANKEL & HAGEN, supra note 31, at 1.
163 Id. at 5.
164 See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at xiv (The Institute of
Medicine noted that mitochondrial DNA “plays a central role in genetic ancestry, [although]
traits that are carried in [nuclear ] DNA are those that in the public understanding constitute
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To the Institute of Medicine, which issued an FDA-commissioned
report on mitochondrial transfer in 2016, there is a “clear line” in
American policy addressing genetic modifications of humans and that
clear line is between modifications that are heritable, such as those
involving germline modification, and those that are not heritable. 165 In
2015, a posting on the White House blog by the White House Director
of the Office of Science and Technology Policy, entitled A Note on
Genome Editing, stated “[t]he Administration believes that altering the
human germline for clinical purposes is a line that should not be crossed
at this time.” 166 However, some legal analyses differentiate between
germline modifications to create “designer babies” and modifications to
cure medical defects. 167 Other ethicists group all germline modifications
together due to a fear that once one germline modification occurs, in
order to treat disease, scientists will undertake subsequent modifications
for nontherapeutic reasons. 168
A more detailed inquiry may reveal that there is a difference to the
American public between using assisted reproductive technology to
have a child with blue eyes instead of brown eyes, for instance, and
using assisted reproductive technology to prevent the passage of
muscular dystrophy to future generations. 169 Currently, it is unclear
the core of genetic relatedness . . . .”); see also WATTS ET AL., supra note 28, at 53, 83–84.
165 See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 88.
166 John P. Holdren, A Note on Genome Editing, WHITE HOUSE BLOG (May 26, 2015, 10:40
AM), https://obamawhitehouse.archives.gov/blog/2015/05/26/note-genome-editing; see also
FRANKEL & HAGEN, supra note 31, at 1 (Although there is no uniform definition of the germ
line, Frankel and Hagen explain that “[t]he term ‘germline’ refers to genetic material that is
hereditable from parent to child.”).
167 See Robertson, supra note 16, at 216 (“The prospect of oocyte cytoplasm transfers thus
requires rethinking the per se ban on germ-line alterations. The question posed is whether
germ-line alterations are always unacceptable. Oocyte transfers suggest that this is not always
the case. Such transfers appear to serve important family and procreative interests, and present
little harm to offspring or others, once the safety and efficacy of the procedure is established.
The fact that the needed therapeutic intervention affects mtDNA in the germ-line has no
independent ethical significance (beyond the concerns that arise with egg donation). It will
prevent mitochondrial disease in offspring, and female offspring will avoid the need to undergo
similar procedures if they reproduce. Indeed, a blanket ban on germ-line effects strictly applied
would condemn somatic cell therapies and many other disease treatments. Many of them affect
the germ-line, albeit indirectly, by enabling persons who would not have survived or been able
to reproduce to do so, thus assuring that genes of that particular germ-line will be passed on.”).
168 See id. at 216–17; see also David Cyranoski, Scientists Sound Alarm over DNA Editing of
Human Embryos, NATURE (Mar. 12, 2015), http://www.nature.com/news/scientists-soundalarm-over-dna-editing-of-human-embryos-1.17110 (“Such research could be exploited for
non-therapeutic modifications. . . . Many groups, including Urnov’s company, are already
using gene-editing tools to develop therapies that correct genetic defects in people (such as by
editing white blood cells). They fear that attempts to produce ‘designer babies’ by applying the
methods to embryos will create a backlash against all use of the technology. . . . But other
scientists disagree with that stance. Although there needs to be a wide discussion of the safety
and ethics of editing embryos and reproductive cells, they say, the potential to eliminate
inherited diseases means that scientists should pursue research.”).
169 While designer babies based on appearance are not a possibility with mitochondrial
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whether the FDA has considered this viewpoint when analyzing the
regulatory treatment of technologies that result in germline
modifications or advanced assisted reproductive technologies. There is
no way to know how clear the line between different types of
modifications actually is without an accurate explanation of the science,
public input, and transparent regulation.
In addition to defining the germline, related questions about
inheritable modifications will surface in discussions of all medical
techniques that modify the germline such as: “Why should it be ethical
to pass on faulty DNA, but unethical to impart healthy DNA?” 170 If at
some point we have the ability to prevent future generations from
inheriting diseases, why shouldn’t we do so? Would individuals who
have defective mitochondria or genes feel a pressure to use scientific
techniques to prevent the transmission of those genes to future
children? What are the implications, from a disability perspective, of
stating that certain traits are undesirable in future generations? 171 An
open public discussion would allow for an informed discussion of our
present scientific capabilities, imminent and likely future capabilities,
and whether there is indeed a line that should not be crossed.
C. Organ Transplantation as Opposed to Genetic Modification:
An Alternative Perspective on Replacing Defective Cell Components
It is possible that using mitochondrial transfer is more like an
organ transplant than a genetic modification or a drug. For example,
mitochondria have also been analogized to the “batteries in a cell,” a
metaphor that resurfaces in discussions of the scientific and ethical
issues related to mitochondrial transfer. 172 Many view mitochondrial
transfer as similar to “changing the batteries in a laptop . . . .” 173
Similarly, the U.K.’s Chief Medical Officer has compared mitochondrial
transfer, it is not a foregone conclusion that one day, mitochondria cannot be engineered to be
“better” such that these energy processing aspects of the cell could be improved. See FRANKEL &
HAGEN, supra note 31, at 7 (“‘[g]ood mitochondrial DNA could facilitate athleticism, and
reduce risk for obesity or diabetes,’ . . . [therefore,] refinement of mitochondrial donation
presents the possibility of a slippery slope from treatment of [mitochondrial ]DNA disease to
enhancement of normal energy production capabilities.” (quoting Rob Waters, Gene Mix in
Monkeys Fixes Defect, Opens New Ethics Debate, BLOOMBERG (Aug. 26, 2009), http://
www.bloomberg.com/apps/news?ppid=2107001&sid=aMTU6ucOhbnw))).
170 Malik, supra note 39.
171 See Elizabeth F. Emens, Framing Disability, 2012 U. ILL. L. REV. 1383 (2012).
172 See OFFICE FOR PUB. MGMT., MEDICAL FRONTIERS: DEBATING MITOCHONDRIA
REPLACEMENT: ANNEX 1: SUMMARY OF EVIDENCE 9 (2013) (reporting members of the public
referring to mitochondria as laptop batteries); WATTS ET AL., supra note 28, at 18.
173 WATTS ET AL., supra note 28, at 78.
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transfer to “changing a car battery . . . .” 174 Thus, in the United Kingdom
where the government executed a five-strand “project” of public
engagement in spite of media coverage sensationalizing mitochondrial
transfer as “three-parent in vitro fertilization,” many members of the
U.K.’s public indicated that they viewed mitochondrial transfer as more
similar to conventional organ or tissue donation (e.g., blood donation,
liver transplant, etc.), than to a eugenics practice. 175
A New York Times article provides a similar American perspective:
“The best analogy for mitochondrial transfer is that of an organ
transplant.” 176 Doctors and scientists “play God . . . every
day . . . [w]hether transplanting naturally faulty hearts, or delivering a
baby by cesarean section when natural birth may be impossible or
dangerous, the very essence of medicine is to right the wrongs of
nature.”177 If the analogy to organ transplant were indeed apt, then
perhaps the technique should be regulated as an organ transplant which
would move it out of the jurisdiction of the U.S. Food and Drug
Administration (assuming this agency was the proper regulator in the
first place), and into the jurisdiction of another agency within the U.S.
Department of Health and Human Services: the Health Resources and
Services Administration. 178 To have information on how many
American scientists and members of the public share this view would be
helpful to policymakers, lawmakers, and regulated entities.
IV. A RANGE OF REGULATORY OPTIONS
There are a number of ways to regulate advanced assisted
reproductive technologies, and ultimately this Article argues that
advanced assisted reproductive technologies should be subject to the
same minimal regulation as other forms of assisted reproductive
technology. The range of regulatory options includes: (1) maintaining
174 Sarah Knapton, Three Parent Babies: Britain Has Breached EU Law, MEPs Warn,
TELEGRAPH (Feb. 21, 2015, 6:00 AM), http://www.telegraph.co.uk/news/11425602/Threeparent-babies-Britain-has-breached-EU-law-MEPs-warn.html.
175 See WATTS ET AL., supra note 28, at 72, 78; discussion infra Part IV; see also Hannah
Darby, Mitochondrial Replacement Consultation: Advice to Government 24 (Human
Fertilisation & Embryology Authority, Paper No. HFEA (20/03/13) 665, 2013) (providing the
recommendation of the U.K.’s HFEA that “mitochondria donors should have a similar status to
that of tissue donors,” which means that “[c]hildren born of mitochondria replacement should
not have a right to access identifying information about the donor when they reach the age of
18”).
176 Malik, supra note 39.
177 Id.
178 About Us, ORGANDONOR.GOV, http://www.organdonor.gov/about-dot.html (last visited
Mar. 3, 2018). For statutory provisions governing organ transplantation, see 42 U.S.C. §§ 273–
74g (2012).
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the status quo, which means the continuance of subterranean
regulation; (2) modifying the status quo so as to ameliorate one or more
of the features that render the FDA’s regulation of advanced assisted
reproductive technology subterranean; and (3) returning the state of
regulation to that which existed before July 6, 2001. This Article
advocates for option three, returning the state of regulation to that
which existed before the FDA issued its letters on July 6, 2001. Option
three would be a state-based approach to the regulation of advanced
assisted reproductive technologies without the additional federal
regulation that has been unique to advanced assisted reproductive
technologies.
Under option one, maintaining the status quo, the FDA would
continue to regulate advanced assisted reproductive technologies in a
subterranean manner and nothing would change. Under this approach,
advanced assisted reproductive technologies (and cloning) would
continue to be illegal in the United States as a result of subterranean
regulation. New technologies would continue to be hindered by such a
regime. For example, in 2013 the FDA sent a letter to OvaScience, a
Massachusetts-based company, stating that the company needed to
submit an investigational new drug application in order to continue its
work on “Augment,” a technology that uses a woman’s own
mitochondria to revitalize her eggs which are then used in in vitro
fertilization. 179 This FDA letter, obtained through FOIA Request 20164882 stated, on the subject of “more than minimal manipulation”:
Our understanding is that your autologous mitochondrial transfer
product, AUGMENT, consists of cells isolated from a biopsy of
ovarian tissue, which are processed to extract mitochondria that are
then introduced into other reproductive tissues during the IVF
process. The removal of mitochondria and introduction into other
reproductive tissue appears to be more than minimal manipulation.
This is based on the limited information available; please note that
the addition of mitochondrial DNA to other reproductive tissue may
raise additional regulatory concerns. 180

I learned of this letter based on media accounts and court
documents related to a shareholder lawsuit which cited to the FDA’s
letter. I was only able to confirm the content of this letter through a
FOIA request that resulted in the transmission of a copy of the letter
along with accompanying additional documents. 181 In one of those
accompanying documents, representatives of the company inquired as
179 See Letter from Celia M. Witten to Alison Lawton, supra note 7; see also Press Release,
OvaScience, First Baby Born with OvaScience’s AUGMENT Fertility Treatment (May 7, 2015),
http://ir.ovascience.com/phoenix.zhtml?c=251343&p=irol-newsArticle&ID=2045382.
180 Letter from Celia M. Witten to Alison Lawton, supra note 7.
181 See id.
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to whether the letter would be
made publicly available and whether FDA intends to issue other
letters. Dr. Witten stated that there are no plans to post the
September 6, 2013 letter; however, she noted that should FDA receive
a FOIA request, FDA would be required to comply with the
disclosure rules and she does not know what the outcome of such a
request would be. In response to the latter question, Dr. Witten
stated that she cannot comment on what might happen in the
future. 182

Thus, as recently as 2013, the FDA was continuing to regulate
nonconventional forms of assisted reproductive technology in a
subterranean manner. 183 If the FDA continues to regulate advanced
assisted reproductive technologies in this manner, then other scientists
may be prevented from providing access to various assisted
reproductive technology techniques in the United States. Furthermore,
if the FDA’s regulation is driven by opposition to genetic modification,
then other developing technologies that use genetic modification as a
method of medical treatment, such as CRISPR-Cas9 or germline editing,
may also be hindered by subterranean regulation.
Option two, would involve the FDA continuing to regulate
advanced assisted reproductive technologies but with increased
transparency and clarity. In other words, the Agency would regulate in a
less subterranean fashion. After years of regulating via letter without a
legal challenge, the Agency might continue regulating advanced assisted
reproductive technologies in a subterranean manner unless stakeholders
successfully petition Congress for clearer legislation; Congress mandates
that the Agency stop regulating AARTs; or researchers ignore the FDA’s
letters and successfully litigate against the Agency in an enforcement
action. 184 Thus, the FDA could wait for mandatory external direction
182 Id.; Telephone Conference with Rachael Anatol & Celia Witten, U.S. Food & Drug
Admin., and Michelle Dipp & Allison Lawton, OvaScience Inc., supra note 17.
183 Id.; see Letter from Mary A. Malarkey to John Zhang, supra note 138. The most recent
2017 letter to a provider of three-parent in vitro fertilization was cited to in the Washington
Post and by numerous news outlets. See Cha, supra note 7.
184 See Wu, supra note 19, at 1850 (noting that “by the 1990s, the Commodity Futures
Trading Commission had begun to think that oversight of certain derivatives products might be
necessary[, b]ut Congress barred regulation based on industry arguments that, among other
reasons, the rapidly changing nature of the industry made regulation ill-advised” (citing Gary
Gensler, History of Derivatives Regulation, Culprit OTCs, COMMODITYONLINE (2010))). “But it
is also critical to remember that… [i]n most circumstances a party unhappy . . . can challenge
the [agency] threat by ignoring it . . . . Id. at 1853; see also K.M. Lewis, Informal Guidance and
the FDA, 66 FOOD & DRUG L.J. 507, 542 (2011) (“Likewise, unlike regulations promulgated
through notice-and-comment rulemaking, obtaining judicial review of guidance documents is
quite difficult due to the finality and ripeness doctrines.”). Another solution, which would
apply not only to the FDA but administrative agencies in general, would be “immediate review
of nonlegislative rules under the Administrative Procedure Act (APA) . . . .” Mark Seidenfeld,
Substituting Substantive for Procedural Review of Guidance Documents, 90 TEX. L. REV. 331, 333
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from Congress or the judiciary that would result in the Agency
regulating more transparently and with a clearer legal foundation, or the
FDA could develop and implement its own transparent best practices
sua sponte or in response to a citizen petition. 185 Thus, one way to
improve transparency and clarity would be for the FDA to clearly
explain the regulatory foundation of the letters sent to AART-providers.
The National Academy of Science’s Institute of Medicine noted
that foreign data could aid the FDA’s assessment of the advantages and
disadvantages of mitochondrial replacement therapy. 186 The FDA
should not only examine the scientific data provided by foreign sources,
such as scientists in the United Kingdom, but it should also consider the
United Kingdom’s process for approving mitochondrial transfer which
included parliamentary briefings and clear explanations of the science
underlying the technology as a part of the country’s extensive public
consultation. 187 In the United Kingdom, where human trials related to
mitochondrial transfer have begun, public consultations revealed that
“[t]hose in favour of the [mitochondrial transfer] techniques felt either
that the only implication of changing the germ line is the removal of
terrible disease from a family, that the germ line would be changed for
the better, or that any negative implications would be outweighed by the
positive ones.” 188 While it is helpful to have the views of another
advanced Western nation’s view on the subject, it is critical that there be
a method to obtain the views of the American public on the many issues
that arise as a result of advanced assisted reproductive technologies and
scientific innovations that may affect the human germline such as
CRISPR-Cas9, especially if perspectives on these ethical issues will
continue to impact federal regulatory decisions.
The FDA, while referred to as an “agency” is, like all organizations,
composed of individuals. If the FDA continues to incorporate ethical
views into regulatory decisions, then it should at least be aware of a
broad spectrum of ethical views and not just the views of its employees.
In the United Kingdom, the agency that wrote the draft regulations on
mitochondrial transfer that were approved by Parliament recommended
(2011).
185 See Warning and Untitled Letters, supra note 4 (“As a result of the Agency’s
Transparency Initiative, the Centers are working to disclose more Untitled Letters on FDA’s
website. The Agency believes that posting additional Untitled Letters may increase public
accountability of firms, which may deter future violations and increase compliance with the
law. However, due to limited resources, the Agency is not able to post all Untitled Letters at this
time.”). For more on citizens’ petitions, see 21 C.F.R. § 10.30 (2017). See generally Michael A.
Carrier & Daryl Wander, Citizen Petitions: An Empirical Study, 34 CARDOZO L. REV. 249
(2012).
186 See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 4–12, 15.
187 See Darby, supra note 175; see also PREVENTING MITOCHONDRIAL DISEASE, supra note
12.
188 Darby, supra note 175, at 16.
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and executed a five-strand “project” of public engagement which
included deliberative public workshops, a public representative survey,
an open consultation questionnaire, open consultation meetings, and a
patient focus group. 189 Following the lead of the United Kingdom,
which approved the clinical use of mitochondrial transfer after public
discussion, the FDA should solicit public input on the ethical issues
resultant from mitochondrial transfer and other advanced assisted
reproductive technologies. The FDA should also aim to not only gain
insights from the public about advanced assisted reproductive
technologies, but also to clearly inform the public of the scientific, legal,
and ethical issues that accompany the clinical use of advanced assisted
reproductive technologies. The example of the United Kingdom also
raises the possibility that a more appropriate governmental structure
could be to have one designated federal agency that addresses all issues
related to human reproduction. However, politics in the United
Kingdom and the United States vary significantly, and such an agency
that concentrates on health-related decision-making would likely be
unwanted in the United States which also does not have a National
Health Service like the United Kingdom does. 190
The National Academy of Science’s Institute of Medicine solicited
public comments on ethical issues related to mitochondrial transfer to
aid in the preparation of its 2016 report. 191 These comments addressed
issues such as “the ethics of heritable genetic modification . . . , patient
perspectives, the role of religion, and how to conduct an ethically
acceptable investigation of [mitochondrial transfer].” 192 “Notice and
comment” is a well-known and crucial part of federal agency
rulemaking. 193 While the FDA did solicit comments on its human tissue
regulations, after years of not regulating reproductive medicine, it could
have been unclear to many observers that these regulations would apply
to human reproductive tissue. Similarly, at the time that the human
tissue regulations were promulgated, mitochondrial transfer had not
received the news coverage that it has today. In other words, there was
no mitochondrial transfer technology available to save human lives in
2001.
At a minimum, if the FDA is going to continue regulating
advanced assisted reproductive technologies based not only on science
but also certain ethical views, then it should use the Federal Register and
media contacts to clearly solicit public comments with a specific focus
See PREVENTING MITOCHONDRIAL DISEASE, supra note 12; Darby, supra note 175.
See About the National Health Service (NHS), NHS, http://www.nhs.uk/NHSEngland/
thenhs/about/Pages/overview.aspx (last updated Apr. 13, 2016).
191 MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 29, at 1–3.
192 Id. at 3.
193 See 5 U.S.C. § 553 (2012).
189
190
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on the ethical issues related to the use of advanced assisted reproductive
technologies. Public comment often involves the use of an online
website, such as regulations.gov, so that members of the public can
provide their comments to the agency in addition to public meetings. If
the FDA continues to regulate AARTs, then unlike the promulgation of
its human tissue regulations where the FDA had one public meeting
related to human bone grafts, the FDA should schedule many public
meetings related to the regulation of AARTs where FDA employees and
technical experts would not only solicit public comments but also
clearly explain the science underlying advanced assisted reproductive
technologies. The FDA should not only hold these meetings in person,
but it should also use web-based technology to allow more members of
the public to not only gain more information about advanced assisted
reproductive technologies, but also to provide their comments. 194
Furthermore, those public comments should focus on the
appropriateness of continuing to regulate AARTs based on the concept
of “minimal manipulation” or “more than minimal manipulation.”
Once an application has been submitted to the FDA, it is too late to
discuss ethical issues due not only to the Agency’s decision-making
process, but also to the way the Agency has structured its regulations on
data and application confidentiality. 195 The FDA’s regulations are so
restrictive that the Agency will not confirm or deny whether an entity
has submitted an investigational new drug application (unless that
company has publicly acknowledged its application). 196 Thus, there is no
public announcement that the FDA is even considering an application
that could be impacted by ethical concerns or a bias against genetic
modifications. Similarly, as noted above in the Introduction, the FDA
does not maintain a complete publicly available database of the Untitled
Letters and their addressees.
It is not impossible for the FDA to regulate clearly and
transparently. Other agencies that contend with not only proprietary
information, but also national security concerns, are able to conduct
public meetings around the country where members of the public
194 See OFFICE OF THE FED. REGISTER, A GUIDE TO THE RULEMAKING PROCESS, https://
www.federalregister.gov/uploads/2011/01/the_rulemaking_process.pdf (“During the comment
period, an agency may also hold public hearings where people can make statements and submit
data. Some agencies operate under laws that require rulemaking hearings. Others may hold
public meetings to collect more information or to help affected groups get a better
understanding of the proposed rule. Many agencies are beginning to use webcasts and
interactive Internet sessions to broaden the audience attending public meetings.”).
195 See 21 C.F.R. §§ 601.50–.51 (2018).
196 Id.; see also 21 C.F.R. § 312.50 (2016) (explaining that a “sponsor” has a specific meaning
to the Agency that signifies that an individual or entity has a pending investigational new drug
application before the FDA). Due to the operation of the Agency’s confidentiality regulations
and record-keeping practices, it is not possible for the public to obtain an accurate count of
how many letters like the July 6, 2001 letter have been issued.
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express their views on licensing actions and maintain comprehensive
databases of the agency’s public documents. For example, the U.S.
Nuclear Regulatory Commission (NRC) has managed to provide online
public access to the “730,000 full-text documents that the NRC has
released since November 1, 1999, and several hundred new documents
are added each day.”197 These available documents include documents
that are not part of licensing dockets and public documents that are part
of licensing dockets (even those license applications that are pending).
The U.S. NRC’s recordkeeping process enables it to provide public
access to any array of documents in addition to screening those dockets
for national security information and proprietary information. 198 The
FDA’s system for responding to FOIA requests reveals that the FDA is
similarly capable of redacting proprietary information before providing
it to the public.
Option three, which I ultimately argue for, is one in which the FDA
does not regulate advanced assisted reproductive technologies at all.
Instead, individual states, if they wish, should enact legislation related to
the legality of AARTs, as states already do with other issues related to
scientific research and family law such as cloning and the legality of
surrogacy contracts. 199 States may face the same difficulty in examining
ethical issues or be similarly constrained by political concerns or
misinformation as the federal government; however, the benefit of a
state-based approach is that there are multiple opportunities (e.g., fifty)
to examine the ethical and scientific concerns underlying advanced
assisted reproductive technologies, even though such an approach may
lead to a domestic form of “reproductive tourism” or forum shopping. 200
Another possible modus operandi for the third option would be
that doctors simply regulate themselves; in spite of this possibility, and
197 ADAMS Public Documents, U.S. NUCLEAR REG. COMM’N, http://www.nrc.gov/readingrm/adams.html (last updated Aug. 9, 2017). The FDA has an “Electronic Reading Room”;
however, that reading room is a website, which provides links to the various centers of the
FDA, which is not easily searchable. See Electronic Reading Room, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/RegulatoryInformation/foi/ElectronicReadingRoom/default.htm
(last
updated Mar. 6, 2017). The Electronic Reading Room is also a part of the Agency’s FOIA
requirements and not an attempt to provide public access to all publicly accessible documents.
See Freedom of Information, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
RegulatoryInformation/FOI (last updated Sept. 27, 2016) (“The 1996 amendments to the
Freedom of Information Act (FOIA) mandate publicly accessible ‘electronic reading rooms’
with agency FOIA response materials and other information routinely available to the public,
with electronic search and indexing features.”).
198 See Information Security, U.S. NUCLEAR REG. COMM’N, http://www.nrc.gov/security/
info-security.html (last updated Aug. 11, 2017).
199 See Gaia Bernstein, Unintended Consequences: Prohibitions on Gamete Donor Anonymity
and the Fragile Practice of Surrogacy, 10 IND. HEALTH L. REV. 291, 296 (2013); Symposium,
Cloning Californians? Report of the California Advisory Committee on Human Cloning, 53
HASTINGS L.J. 1143 (2002).
200 For more on reproductive tourism or the broader concept of “medical tourism,” see I.
Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309 (2012).
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in light of past well-known instances of physicians and researchers
failing to adhere to ethical guidelines for human subjects research or
general medical norms, I still advocate for some state oversight, however
minimal. 201 It is possible that this framework already exists through state
statutes addressing research and informed consent; thus, the state-based
regulation of AARTs does not necessarily require the enactment of
additional regulations specific to AARTs. While there are some
disadvantages to a state-based regulatory approach, those disadvantages
do not outweigh the advantages of a state-based approach, which would
still provide for informed consent and other patient protections. 202
There are several reasons why the FDA should not regulate
AARTs. First, it is likely that the FDA does not have jurisdiction over
advanced assisted reproductive technologies at all. This characterization
stems not only from confusion over whether federal statutory provisions
apply to advanced assisted reproductive technologies, but also from the
fact that advanced assisted reproductive technologies do not fall within
the usual categories regulated by the FDA: food, drugs, medical devices,
and biologics. 203 Second, even if the Agency does have jurisdiction over
advanced assisted reproductive technologies, the process of asserting
jurisdiction has been marked by uncertainty, opacity, and
counterintuitive regulations. 204 Thus, even if the FDA has jurisdiction
over AARTs, the Agency’s current regulatory approach of treating
AARTs like drugs or biologics does not adequately consider their
accompanying legal and ethical issues and the impact of the FDA’s
201 See, e.g., The Tuskegee Timeline, CENTERS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/tuskegee/timeline.htm (last updated Aug. 30, 2017) (“In July 1972, an
Associated Press story about the Tuskegee Study caused a public outcry that led the Assistant
Secretary for Health and Scientific Affairs to appoint an Ad Hoc Advisory Panel to review the
study. The panel had nine members from the fields of medicine, law, religion, labor, education,
health administration, and public affairs. The panel found that the men had agreed freely to be
examined and treated. However, there was no evidence that researchers had informed them of
the study or its real purpose. In fact, the men had been misled and had not been given all the
facts required to provide informed consent. The men were never given adequate treatment for
their disease. Even when penicillin became the drug of choice for syphilis in 1947, researchers
did not offer it to the subjects. The advisory panel found nothing to show that subjects were
ever given the choice of quitting the study, even when this new, highly effective treatment
became widely used.”); see also Dale Keiger, Immortal Cells, Enduring Issues, JOHNS HOPKINS
MAGAZINE (June 2, 2010), http://archive.magazine.jhu.edu/2010/06/immortal-cells-enduringissues (reviewing Rebecca Skloot’s The Immortal Life of Henrietta Lacks: “Text on the front
cover of Skloot’s book reads, ‘Doctors took her cells without asking.’ The inside flap continues,
‘Henrietta’s family did not learn of her “immortality” until more than 20 years after her death,
when scientists investigating HeLa began using her husband and children in research without
informed consent. And though the cells had launched a multimillion-dollar industry that sells
human biological materials, her family never saw any of the profits.’ A significant segment of
the public harbors a deeply rooted mistrust of medical research.”).
202 See Jessica De Bord, Informed Consent, UNIV. WASH. SCH. MED., https://
ashin.washington.edu/bioethx/topics/consent.html (last updated Mar. 7, 2014).
203 See What Does FDA Regulate?, supra note 22.
204 See supra Part II; infra Appendix A.
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extant regulatory structure on scientific innovation, reproductive rights,
and medical ethics. Under the current regulatory structure, the FDA is
able to inject ethical concerns into a regulatory procedure that should
focus on safety and efficacy and not the ethical views of a select number
of federal employees.
By not subjecting advanced assisted reproductive technologies to
additional regulations, advanced assisted reproductive technologies
would be subject to the same regulatory regime that they were subject to
before July 6, 2001 (the date on which the FDA sent letters to physicians
providing cytoplasmic transfer to patients in the United States). Under
this regime, advanced assisted reproductive technologies would be
regulated in the same manner as conventional assisted reproductive
technologies. Thus, advanced assisted reproductive technologies would
be subject to the standard ethical norms of medical practice and
scientific research, including informed consent. The statements of
physicians at the FDA’s 2002 Advisory Committee meeting indicates
that physicians had already incorporated these concerns into the
consent forms provided to patients who were undergoing cytoplasmic
transfer. In sum, I argue for a regulatory regime in which advanced
assisted reproductive technologies are not subject to subterranean
regulation or any other sort of unique federal regulation.
CONCLUSION
The field of assisted reproductive technology has generated
controversy since its inception. 205 When in vitro fertilization was first
introduced, there was much opposition to the technique.206
Nevertheless, today it is generally accepted ethically and legally in the
United States, United Kingdom, and many other countries. 207
Mitochondrial transfer faces the same public hurdles as in vitro
fertilization did in the 1970s and 1980s, in addition to additional ethical

205 See CLONING HUMAN BEINGS, supra note 115, at 5 (“Artificial insemination by donor, for
example, was considered a form of adultery when first introduced in the 1940s. . . . When
prenatal diagnosis was introduced in the late 1960s, the public simultaneously welcomed the
opportunity to prevent lethal disease in newborns but worried about the use of such techniques
to select ‘vanity’ characteristics or nonmedical traits in offspring. The birth of Louise Brown,
conceived via in vitro fertilization, in 1978 was another dramatic event, providing a new and
controversial means to parenthood.”).
206 See Connor, supra note 12.
207 See Press Release, Nobel Assembly at Karolinska Institutet, The Nobel Prize in
Physiology or Medicine 2010 to Robert G. Edwards for the Development of In Vitro
Fertilization (Oct. 4, 2010), https://www.nobelprize.org/nobel_prizes/medicine/laureates/2010/
press.html.
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hurdles related to eugenics, cloning, and germline modification. 208
CRISPR-Cas9 and other methods of gene editing will also face these
public hurdles in addition to the barriers presented by subterranean
regulation.
The FDA has been regulating cloning and advanced assisted
reproductive technologies through letters for over twenty years,
although it has never provided proof of jurisdiction. To regulate in a
subterranean fashion can deter research and American patients’ access
to life-saving techniques. Because the FDA’s interpretation of what it
can regulate is contrary to researchers’ and attorneys’ understanding of
what the FDA regulates, these letters surprise researchers by essentially
asserting that their AART research protocols, which would generally not
be regulated by the FDA, are essentially the same as drugs. The letters
sent by the FDA to researchers do not threaten enforcement action but
act as a de facto barrier to research and the clinical use of AARTs, as
these letters represent an agency statement that an individual or entity is
violating federal law.
In addition to regulating through letters, the FDA has structured its
confidentiality regulations and recordkeeping system in a way that
prevents the public from easily finding the letters that it issues to AART
providers. Additionally, the Agency has promulgated regulations that
make it such that if the Agency is not currently considering an
application for premarket approval, then there is no docket available to
the public and certainly no public access to a docket when there is an
application pending. However, if the Agency is regulating through
subterranean actions that have the effect of regulation, then the public
needs to at least be aware of those Agency actions, and the evidence of
those actions should be easily searchable. Furthermore, whether the
FDA believes that advanced assisted reproductive technologies are
analogous to biologics or drugs (or actually are biologics or drugs), it
should be clear to the public how the FDA categorizes these
technologies and why. 209
208 See Bazian, Thousands of UK Women Could Benefit from “Three-Person” IVF, NHS
CHOICES (Jan. 29, 2015), http://www.nhs.uk/news/2015/01January/Pages/Thousands-of-UKwomen-could-benefit-from-three-person-IVF.aspx; Interview: Dr. Jamie Grifo, PBS , http://
www.pbs.org/wgbh/pages/frontline/shows/fertility/interviews/grifo.html (last visited Mar. 4,
2018); Connor, supra note 12; see also Bazian, Draft Regulations on “Three-Parent” IVF
Published, NHS CHOICES (Feb. 28, 2014), http://www.nhs.uk/news/2014/02February/Pages/
Draft-regulations-on-three-parent-IVF-published.aspx (“Opponents of these types of
treatments [such as mitochondrial transfer and the use of assisted reproductive technology] cite
what can be broadly summarised as the ‘slippery slope’ argument; this suggests that once a
precedent has been set for altering the genetic material of an embryo prior to implantation in
the womb, it is impossible to predict how these types of techniques might be used in the future.
Similar concerns were raised, however, when IVF treatments were first used during the 1970s;
today, IVF is generally accepted.”); Press Release, Nobel Assembly at Karolinska Institutet,
supra note 207.
209 Both Investigational New Drug Applications and Biologics License Applications involve
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The current regulatory environment also deprives the public of a
clear understanding of how the multitude of ethical and legal issues
resultant from the clinical use of advanced assisted reproductive
technologies are incorporated into legal regulation. The increase in the
number of regulations applicable to human reproductive tissue has not
corresponded with a clearly articulated understanding of how the FDA
has jurisdiction over advanced assisted reproductive technologies.
Currently, there is no baseline in the United States for understanding
what the general consensus might be on the ethical issues related to
these techniques, as an informed and national discussion of these ethical
issues has not occurred. Instead, individual ethical issues, such as
embryo destruction, continue to arise in the context of regulatory
decisions; however, the issues are never comprehensively addressed, nor
is their impact on regulatory decision-making clearly identifiable.
Furthermore, to include reproductive tissues in regulations affecting all
human tissue inadequately considers the unique nature of human
reproductive tissue. The regulation of human reproductive tissue and
reproduction in general gives rise to a number of concerns including
legal concerns related to reproductive rights. Thus, not only is clear
decision-making a best practice for federal agencies, but it is crucial
when federal agency decisions may somehow impact reproductive
rights.
APPENDIX A: LETTER TO SPONSORS / RESEARCHERS—HUMAN CELLS
USED IN THERAPY INVOLVING THE TRANSFER OF GENETIC MATERIAL BY
MEANS OTHER THAN THE UNION OF GAMETE NUCLEI
Department of Health and Human Services 210
Public Health Service
Food and Drug Administration
the same form; however, the applications are reviewed by different FDA staff, and different
statutes govern the approval of each. See Frequently Asked Questions About Therapeutic
Biological Products, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/drugs/
developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/
therapeuticbiologicapplications/ucm113522.htm (last updated July 7, 2015) (“Whereas a new
drug application (NDA) is used for drugs subject to the drug approval provisions of the FDC
Act, a biologics license application (BLA) is required for biological products subject to licensure
under the PHS Act. FDA form 356h is used for both NDA and BLA submissions. FDA approval
to market a biologic is granted by issuance of a biologics license.”); see also DEP’T OF HEALTH &
HUMAN SERVS., U.S. FOOD & DRUG ADMIN., FORM FDA 356H, APPLICATION TO MARKET A
NEW OR ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE (2017), http://www.fda.gov/
downloads/AboutFDA/ReportsManualsForms/Forms/UCM082348.pdf.
210 Letter from Kathryn C. Zoon, Dir., Ctr. for Biologics Evaluation & Research, U.S. Food &
Drug Admin., to Sponsors/Researchers (July 6, 2001), http://www.fda.gov/BiologicsBlood
Vaccines/SafetyAvailability/ucm105852.htm.
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1401 Rockville Pike
Rockville, MD 20852-1448
July 6, 2001
Dear Sponsor / Researcher:
We want to advise you that the Food and Drug Administration (FDA)
has jurisdiction over human cells used in therapy involving the transfer
of genetic material by means other than the union of gamete nuclei.
Examples of such genetic material include, but are not limited to:
• cell nuclei (e.g., for cloning),
• oocyte nuclei,
• ooplasm, which contains mitochondrial genetic material, and
• genetic material contained in a genetic vector, transferred
into gametes or other cells.
The use of such genetically manipulated cells (and/or their derivatives)
in humans constitutes a clinical investigation and requires submission
of an Investigational New Drug application (IND) to FDA. We wish to
inform you of the FDA regulatory process governing clinical
investigations, which includes requirements applicable to
manufacturing processes, the study of the safety and efficacy of such
cells, and the protection of human participants in such studies. We can
advise you whether or not your activities require submission of an IND.
If what you are doing or plan to do does require an IND, we would be
pleased to provide you with information and guidance regarding filing
such an application.
FDA’s regulations on investigational new drugs, including those for the
submission and review of an IND are described in Title 21 of the Code
of Federal Regulations (CFR), Parts 50, 56, and 312. The agency has
provided notice of the applicability of these requirements to cellular and
tissue-based products in many public forums and in various published
documents available at http://www.fda.gov/cber, including the
following:
• A Federal Register (FR) notice describing FDA’s authority
over cell and gene therapy products (“Application of Current
Statutory Authorities to Human Somatic Cell Therapy
Products and Gene Therapy Products,” October 14, 1993, 58
FR 53248) (PDF - 489 KB).
• A comprehensive regulatory program for the regulation of
human cellular and tissue-based products, based on a tiered,
risk-based assessment (“A Proposed Approach to the
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Regulation of Cellular and Tissue-Based Products,” March 4,
1997, 62 FR 9721).
A final rule that establishes the criteria for regulation of
human cells, tissues, and cellular and tissue based products
(HCT/Ps), including reproductive cells and tissues, published
on January 19, 2001 (66 FR 5447). This rule also describes
which HCT/Ps will be regulated solely under 21 CFR Part
1271, the regulations to prevent communicable disease
transmission authorized by section 361 of the Public Health
Service Act. HCT/Ps that do not meet the criteria under Part
1271 will be regulated as biological products, drugs, or
devices under section 351 of the Public Health Service Act
and/or the Food Drug and Cosmetic Act.
“Suitability Determination for Donors of Human Cellular
and Tissue-Based Products; Proposed Rule.” September 30,
1999 (64 FR 52696).
“Current Good Tissue Practice for Manufacture of Human
Cellular and Tissue-Based Products; Inspection and
Enforcement; Proposed Rule” January 8, 2001 (66 FR 1508).

If you are unable to access the internet to obtain information on
submitting an IND to the FDA, please call or write and we’ll supply you
with the needed information:
Center for Biologics Evaluation and Research
Office of Communication, Training & Manufacturers Assistance
Manufacturers Assistance and Technical Training Branch
1401 Rockville Pike, HFM-44
Rockville, MD 20852-1448
800-835-4709 or 301-827-1800
matt@cber.fda.gov
The specific information required in an IND will depend upon the cells
under investigation and on the phase of study. For assistance in
determining whether you need to file an IND submission and in
preparation of a submission, please contact Wendy Aaronson,
Application Administration Branch Chief, Division of Application
Review and Policy, at 301-827-5101.
Sincerely,
—signature—
Kathryn C. Zoon, Ph.D.
Director
Center for Biologics Evaluation and Research
Food and Drug Administration
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APPENDIX B: LETTER ABOUT HUMAN CLONING
October 26, 1998 211
Dear Colleague:
The purpose of this letter is to confirm to institutional review boards
(IRBs) that the Food and Drug Administration (FDA) has jurisdiction
over clinical research using cloning technology to create a human being,
and to inform IRBs of the FDA regulatory process that is required
before any investigator can proceed with such a clinical investigation.
This letter is being sent to IRBs at this time because of reports in the
media that scientists are contemplating the use of cloning technology to
create human beings. As described more fully below, the appropriate
mechanism to pursue a clinical investigation using cloning technology is
the submission of an investigational new drug application (IND) to
FDA.
Clinical research using cloning technology to create a human being is
subject to FDA regulation under the Public Health Service Act and the
Federal Food, Drug, and Cosmetic Act. Under these statutes and FDA’s
implementing regulations, before such research may begin, the sponsor
of the research is required to submit to FDA an IND describing the
proposed research plan; to obtain authorization from a properly
constituted and functioning IRB; and to obtain a commitment from the
investigators to obtain informed consent from all human subjects of the
research. Such research may proceed only when an IND is in effect.
Since FDA believes that there are major unresolved safety questions
pertaining to the use of cloning technology to create a human being,
until those questions are appropriately addressed in the IND, FDA
would not permit any such investigation to proceed.
FDA may prohibit a sponsor from conducting a study proposed in an
IND application (often referred to as placing the study on “clinical
hold”) for a variety of reasons. If the Agency finds that “human subjects
are or would be exposed to an unreasonable and significant risk of
illness or injury,” that would be sufficient reason to put a study on
clinical hold. Other reasons listed in the regulations include “the IND
does not contain sufficient information required . . . to address the risks
to subjects of the proposed studies,” or “the clinical investigators . . . are
not qualified by reason of their scientific training and experience to
conduct the investigation.”

211

Nightingale, supra note 72.
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The procedures and requirements governing the use of investigational
new drugs, including those for the submission and review of INDs, are
set forth in Title 21 of the Code of Federal Regulations (CFR), Part 312.
Additional responsibilities of the sponsor of an IND include: selecting
qualified investigators and overseeing the conduct of the investigators;
ensuring that the investigations are performed in accordance with the
protocols of the IND; submitting adverse experience reports and annual
reports; and other duties as outlined in the regulations. The
responsibilities of an investigator include: ensuring that the study is
conducted in accordance with the protocols; obtaining informed
consent from study subjects; and ensuring that an IRB that complies
with the requirements of 21 CFR Part 56 reviews and approves the
proposed clinical study and the informed consent form and procedures
for obtaining informed consent, among other requirements specified in
the regulations. IRBs and clinical investigators may obtain a copy of the
current “Information Sheets for IRBs and Clinical Investigators” by
contacting FDA’s Office of Health Affairs (301-827-1685), through the
world wide web (http://www.fda.gov/oha/IRB/toc.html*) or through a
Fax-on-demand system (1-800-993-0098).
We hope the above information is useful to you. Please feel free to share
this information with others at your institution.
Sincerely yours,
/s/
Stuart L. Nightingale, M.D.
Associate Commissioner
APPENDIX C: UNTITLED LETTER (BIOLOGIC)
March 12, 2015 212
VIA FACSIMILE AND UPS (UNITED PARCEL SERVICE)
Samuel Simons
Regulatory Manager
Protein Sciences Corporation
1000 Research Parkway
Meriden, CT 06450
Re: Flublok (Influenza Vaccine)

212

Letter from Robert A. Sausville to Samuel Simons, supra note 65.
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BLA STN# 125285
Dear Mr. Simons:
The Advertising and Promotional Labeling Branch (APLB) at the U.S.
Food and Drug Administration’s (FDA) Center for Biologics Evaluation
and Research (CBER) has reviewed the video interview with CEO Dr.
Manon Cox, entitled ‘Watch us on Lifetime – The Balancing Act,’ that is
posted on the website www.flublok.com by your company, Protein
Sciences Corporation (Protein Sciences). This promotional material is
in violation of the Federal Food, Drug, and Cosmetic Act (Act) and
implementing regulations because it overstates the efficacy of Flublok
(Influenza Vaccine) and omits the risks associated with Flublok.
Therefore, this material misbrands Flublok under sections 502(a) and
201(n) of the Act, 21 U.S.C. § 352(a) and § 321(n), and FDA
implementing regulations, Cf. 21 CFR 202.1(e)(6)(i) and (e)(7)(viii).
Background
According to the FDA-approved prescribing information (PI), Flublok
is a vaccine indicated for active immunization against disease caused by
influenza virus subtypes A and type B contained in the vaccine. Flublok
is approved for use in persons 18 years of age and older.
The Warnings and Precautions section of the PI includes, but is not
limited to, the following risks:
Appropriate medical treatment and supervision must be available to
manage possible anaphylactic reactions following administration of
Flubok.
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a
prior influenza vaccine, the decision to give Flublok should be based on
careful consideration of potential benefits and risks.
Vaccination with Flublok may not protect all vaccine recipients.
Page 2 – STN 125285
The Adverse Reactions section includes, but is not limited to, the
following:
In adults 18 through 49 years of age, the most common (≥10%)
injection-site reaction was pain (37%); the most common (≥10%)
solicited systemic adverse reactions were headache (15%), fatigue (15%)
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and muscle pain (11%).
In adults 50 through 64 years of age, the most common (≥10%)
injection site reaction was pain (32%); the most common (≥10%)
solicited systemic adverse reactions were headache (17%), fatigue (13%),
and muscle pain (11%).
In adults 65 years of age and older, the most common (≥10%) injection
site reaction was pain (19%); the most common (≥10%) solicited
systemic adverse reactions were fatigue (13%) and headache (10%).
Misleading Efficacy Claim
Promotional materials are misleading if they represent or suggest that a
product is more effective than has been demonstrated by substantial
evidence or substantial clinical experience. Your video, entitled ‘Watch
us on Lifetime – The Balancing Act,’ presents an interview with Dr. Cox
in which she states that Protein Sciences ‘is able to put three times more
protein in there, so it is also a high dose vaccine. More protein means your
body will form more antibodies that will help you fight the flu.’ This claim
misleadingly implies that the higher antigen content of Flublok
translates into greater protection. Currently, there is only one licensed
high-dose influenza vaccine, which is indicated for active immunization
of persons 65 years of age and older against influenza disease caused by
influenza virus subtypes A and type B contained in the vaccine. FDA is
unaware of any adequate and well-controlled clinical trials that
substantiate this claim for your product. Furthermore, in our October
20, 2014 letter to Protein Sciences on this issue, we provided advisory
comments regarding the misleading implication of this claim. We
reiterated our comments in a teleconference with Dr. Manon Cox on
November 10, 2014.
Omission of Risk Information
Promotional materials are misleading if they fail to reveal facts that are
material in light of representations made by the materials or with
respect to consequences that may result from the use of the drug as
recommended or suggested by the materials.
Specifically, the video presents multiple efficacy claims for Flublok, such
as ‘helps you fight the flu,’ but fails to present any important safety
information from the PI.
Conclusion and Requested Actions

1296

CARDOZO LAW REVIEW

[Vol. 39:1239

For the reasons discussed above, your promotional material misbrands
Flublok under sections 502(a) and 201(n) of the Act, 21 U.S.C. § 352(a)
and § 321(n), and FDA implementing regulations, Cf. 21 CFR
202.1(e)(6)(i) and (e)(7)(viii).
We request that Protein Sciences immediately cease the dissemination
of this violative promotional material for Flublok, as well as
promotional materials with the same or similar claims and
representations. Please submit a written response within ten (10)
business days of the
Page 3 – STN 125285
date of this letter, stating whether you intend to comply with this
request, listing all violative promotional materials for Flublok and
explaining your plan for discontinuing use of such materials. Please
direct your response to Lisa Stockbridge, Ph.D., Branch Chief at the
Food and Drug Administration, Center for Biologics Evaluation and
Research, Office of Compliance and Biologics Quality, Division of Case
Management, Advertising and Promotional Labeling Branch, 10903
New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. In
all future correspondence regarding this matter, please refer to the
BLA/STN number. We remind you that only written communications
are considered official responses.
The violations discussed in this letter do not necessarily constitute an
exhaustive list. It is your responsibility to ensure that your promotional
materials for Flublok comply with each applicable requirement of the
Act and FDA implementing regulations.
If you choose to revise your promotional materials, APLB is willing to
assist you in assuring that your revised materials comply with applicable
provisions of the Act by reviewing your revisions before you use them in
promotion.
Sincerely,
Robert A. Sausville
Director, Division of Case Management
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research
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APPENDIX D: WARNING LETTER ISSUED TO 23ANDME, INC.
Nov 22, 2013 213
Ann Wojcicki
CEO
23andMe, Inc.
1390 Shoreline Way
Mountain View, CA 94043
Document Number: GEN1300666
Re: Personal Genome Service (PGS)
WARNING LETTER
Dear Ms. Wojcicki,
The Food and Drug Administration (FDA) is sending you this letter
because you are marketing the 23andMe Saliva Collection Kit and
Personal Genome Service (PGS) without marketing clearance or
approval in violation of the Federal Food, Drug and Cosmetic Act (the
FD&C Act).
This product is a device within the meaning of section 201(h) of the
FD&C Act, 21 U.S.C. 321(h), because it is intended for use in the
diagnosis of disease or other conditions or in the cure, mitigation,
treatment, or prevention of disease, or is intended to affect the structure
or function of the body. For example, your company’s website at
www.23andme.com/health (most recently viewed on November 6, 2013)
markets the PGS for providing “health reports on 254 diseases and
conditions,” including categories such as “carrier status,” “health risks,”
and “drug response,” and specifically as a “first step in prevention” that
enables users to “take steps toward mitigating serious diseases” such as
diabetes, coronary heart disease, and breast cancer. Most of the intended
uses for PGS listed on your website, a list that has grown over time, are
medical device uses under section 201(h) of the FD&C Act. Most of
these uses have not been classified and thus require premarket approval
or de novo classification, as FDA has explained to you on numerous
occasions.

213 Letter from Alberto Gutierrez, Dir., Office of In Vitro Diagnostics & Radiological Health,
U.S. Food & Drug Admin., to Ann Wojcicki, Chief Exec. Officer, 23andMe, Inc. (Nov. 22,
2013), http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm).
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Some of the uses for which PGS is intended are particularly concerning,
such as assessments for BRCA-related genetic risk and drug responses
(e.g., warfarin sensitivity, clopidogrel response, and 5-fluorouracil
toxicity) because of the potential health consequences that could result
from false positive or false negative assessments for high-risk
indications such as these. For instance, if the BRCA-related risk
assessment for breast or ovarian cancer reports a false positive, it could
lead a patient to undergo prophylactic surgery, chemoprevention,
intensive screening, or other morbidity-inducing actions, while a false
negative could result in a failure to recognize an actual risk that may
exist. Assessments for drug responses carry the risks that patients
relying on such tests may begin to self-manage their treatments through
dose changes or even abandon certain therapies depending on the
outcome of the assessment. For example, false genotype results for your
warfarin drug response test could have significant unreasonable risk of
illness, injury, or death to the patient due to thrombosis or bleeding
events that occur from treatment with a drug at a dose that does not
provide the appropriately calibrated anticoagulant effect. These risks are
typically mitigated by International Normalized Ratio (INR)
management under a physician’s care. The risk of serious injury or
death is known to be high when patients are either non-compliant or
not properly dosed; combined with the risk that a direct-to-consumer
test result may be used by a patient to self-manage, serious concerns are
raised if test results are not adequately understood by patients or if
incorrect test results are reported.
Your company submitted 510(k)s for PGS on July 2, 2012 and
September 4, 2012, for several of these indications for use. However, to
date, your company has failed to address the issues described during
previous interactions with the Agency or provide the additional
information identified in our September 13, 2012 letter for (b)(4) and in
our November 20, 2012 letter for (b)(4), as required under 21 CFR
807.87(1). Consequently, the 510(k)s are considered withdrawn, see 21
C.F.R. 807.87(1), as we explained in our letters to you on March 12,
2013 and May 21, 2013. To date, 23andMe has failed to provide
adequate information to support a determination that the PGS is
substantially equivalent to a legally marketed predicate for any of the
uses for which you are marketing it; no other submission for the PGS
device that you are marketing has been provided under section 510(k) of
the Act, 21 U.S.C. § 360(k).
The Office of In Vitro Diagnostics and Radiological Health (OIR) has a
long history of working with companies to help them come into
compliance with the FD&C Act. Since July of 2009, we have been
diligently working to help you comply with regulatory requirements
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regarding safety and effectiveness and obtain marketing authorization
for your PGS device. FDA has spent significant time evaluating the
intended uses of the PGS to determine whether certain uses might be
appropriately classified into class II, thus requiring only 510(k)
clearance or de novo classification and not PMA approval, and we have
proposed modifications to the device’s labeling that could mitigate risks
and render certain intended uses appropriate for de novo classification.
Further, we provided ample detailed feedback to 23andMe regarding the
types of data it needs to submit for the intended uses of the PGS. As part
of our interactions with you, including more than 14 face-to-face and
teleconference meetings, hundreds of email exchanges, and dozens of
written communications, we provided you with specific feedback on
study protocols and clinical and analytical validation requirements,
discussed potential classifications and regulatory pathways (including
reasonable submission timelines), provided statistical advice, and
discussed potential risk mitigation strategies. As discussed above, FDA
is concerned about the public health consequences of inaccurate results
from the PGS device; the main purpose of compliance with FDA’s
regulatory requirements is to ensure that the tests work.
However, even after these many interactions with 23andMe, we still do
not have any assurance that the firm has analytically or clinically
validated the PGS for its intended uses, which have expanded from the
uses that the firm identified in its submissions. In your letter dated
January 9, 2013, you stated that the firm is “completing the additional
analytical and clinical validations for the tests that have been submitted”
and is “planning extensive labeling studies that will take several months
to complete.” Thus, months after you submitted your 510(k)s and more
than 5 years after you began marketing, you still had not completed
some of the studies and had not even started other studies necessary to
support a marketing submission for the PGS. It is now eleven months
later, and you have yet to provide FDA with any new information about
these tests. You have not worked with us toward de novo classification,
did not provide the additional information we requested necessary to
complete review of your 510(k)s, and FDA has not received any
communication from 23andMe since May. Instead, we have become
aware that you have initiated new marketing campaigns, including
television commercials that, together with an increasing list of
indications, show that you plan to expand the PGS’s uses and consumer
base without obtaining marketing authorization from FDA.
Therefore, 23andMe must immediately discontinue marketing the PGS
until such time as it receives FDA marketing authorization for the
device. The PGS is in class III under section 513(f) of the FD&C Act, 21
U.S.C. 360c(f). Because there is no approved application for premarket
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approval in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C.
360e(a), or an approved application for an investigational device
exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C.
360j(g), the PGS is adulterated under section 501(f)(1)(B) of the FD&C
Act, 21 U.S.C. 351(f)(1)(B). Additionally, the PGS is misbranded under
section 502(o) of the Act, 21 U.S.C. § 352(o), because notice or other
information respecting the device was not provided to FDA as required
by section 510(k) of the Act, 21 U.S.C. § 360(k).
Please notify this office in writing within fifteen (15) working days from
the date you receive this letter of the specific actions you have taken to
address all issues noted above. Include documentation of the corrective
actions you have taken. If your actions will occur over time, please
include a timetable for implementation of those actions. If corrective
actions cannot be completed within 15 working days, state the reason
for the delay and the time within which the actions will be completed.
Failure to take adequate corrective action may result in regulatory
action being initiated by the Food and Drug Administration without
further notice. These actions include, but are not limited to, seizure,
injunction, and civil money penalties.
We have assigned a unique document number that is cited above. The
requested information should reference this document number and
should be submitted to:
James L. Woods, WO66-5688
Deputy Director
Patient Safety and Product Quality
Office of In vitro Diagnostics and Radiological Health
10903 New Hampshire Avenue
Silver Spring, MD 20993
If you have questions relating to this matter, please feel free to call
Courtney Lias, Ph.D. at 301-796-5458, or log onto our web site at
www.fda.gov for general information relating to FDA device
requirements.
Sincerely yours,
/S/
Alberto Gutierrez
Director
Office of In vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

